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         Executive summary 
 
Bacterial lipoprotein biogenesis, inner membrane translocation and maturation 
are all events occurring with a common process in all gram negative bacteria. 
The mechanism responsible for lipoprotein sorting is conserved among bacterial 
species, generally involving the Lol transport machinery. However, the final 
destination of lipoproteins may vary among species. In E. coli, lipoproteins can be 
retained in the outer leaflet of the inner membrane, thanks to the presence of 
specific amino acid residues (retention signals) which prevent lipoproteins from 
binding to the Lol transport system. In the absence of the retention signals, 
lipoproteins leave the inner membrane, cross the periplasm or reach the inner 
leaflet of the outer membrane. In N. meningitidis, lipoproteins that reach the outer 
membrane undergo an additional step, which ultimately leads to their exposition 
on the cell surface. The mechanism by which lipoprotein exposition occurs 
remains to be fully elucidated. The involvement of a specific enzyme, a “flippase”, 
that moves lipoproteins from the inner to the outer leaflet of the outer membrane 
has been postulated but its existence has never been proved.  
In an attempt to shed light on the mechanism of lipoprotein surface exposition, in 
this work we selected two N. meningitidis lipoproteins, fHbp and NHBA, and we 
first asked the question whether when expressed in E. coli, they could reach the 
outer membrane. The proteins were both efficiently expressed in E. coli and 
inserted in the outer membrane, as determined by the fact that the proteins were 
found associated to Outer Membrane Vesicles (OMVs), vesicles that are naturally 
released by gram-negative bacteria through a budding out process of the outer 
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membrane. However, when their precise localization was investigated they were 
both found in the membrane but with a different orientation:  fHbp was exposed 
on the surface while NHBA was not. These results suggest that fHbp has specific 
signals that promote its translocation without the aid of a specific transport 
machinery. In an attempt to identify such “transport signatures” a number of 
amino acid deletions/substitutions were created at the N terminus of the protein 
but none of them affected the capacity of fHbp to be exposed. We next took 
advantage of the available 3D structure of fHbp to further investigate the sorting 
mechanism. fHbp is organized in three structural domains, referred to as domain 
A, B, and C. Therefore we created specific domain deletions and we investigated 
which of them are potentially involved in the exposition process. Interestingly,  
based on the results obtained, we hypothesized that domain A carries the 
information necessary to allow the translocation of fHbp to the cell surface. 
The fact that fHbp protrudes out of the cell surface can be biotechnologically 
exploited to bring foreign proteins on the surface of E. coli cells by creating 
protein chimeras. To test this possibility,  we selected three proteins, including the 
domain 3 of GBS59 pilus protein from Streptococcus agalactiae, Staphilococcus 
aureus fhuD2 and Staphilococcus aureus spaDEABC and then we fused them to 
full length fHbp and/or to fHbp domain A. 
The results indicate that all proteins were efficiently delivered to the outer 
membrane. Furthermore, the D3 domain of GBS59 was also exposed on the 
surface of E. coli and E. coli-derived OMVs. 
10 
 
Alltogether our data indicate that fHbp can be exploited to direct foreign proteins 
to the outer membrane. 
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1) INTRODUCTION 
 
1.1 Organization of Gram-negative envelope 
The cell envelope of gram-negative bacteria consists of two membranes, the 
Inner Membrane (IM) and the Outer Membrane (OM), that are separated by the 
periplasm containing the peptidoglycan layer (Bos M.P. et al., 2007) (Figure 1). 
The two membranes have an entirely different structure and composition. 
Whereas the IM is organized in two phospholipid-containing leaflets, the OM is an 
asymmetrical bilayer, consisting of phospholipids and lipopolysaccharides (LPS) 
in the inner and outer leaflets, respectively (Ruiz N. et al., 2009).  
 
 
 
Figure 1 – Schematic representation of Gram negative bacteria envelope                      
(Natividad Ruiz et al., 2009) 
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IM, OM and periplasm contain a number of proteins with key biological functions. 
Most of the proteins destined to these compartments are synthesized in the 
cytoplasm as precursors with N-terminal leader peptides (LP) and are 
translocated across the inner membrane following two distinct export pathways 
(Okuda S. et al., 2011). The Sec-dependent (Sec) secretory pathway is the 
predominant route of protein transport (Driessen A.J.M. et al., 2008). The Sec 
machinery recognizes LP of secreted proteins during the translation process and 
transport across the IM occurs while proteins are still in an unfolded 
conformation. Once translocated through the IM, specific leader peptidases 
remove LP and folded mature proteins are either released into the periplasmic 
space or directed to the membrane compartments. By contrast, the more recently 
discovered Twin arginine traslocation system (Tat) promotes the transport from 
the cytoplasm to the periplasm of folded and even oligomeric proteins (Sargent F. 
et al., 2005). The LPs of the proteins translocated via the Tat system are 
characterized by the presence of an essential twin-arginine motif (Okuda S. et al., 
2011). 
As said above, once translocated through the IM, proteins are either retained in 
the periplasm or, in the case of membrane proteins, they reach their final 
destination using specific transport machineries. There are two main classes of 
membrane proteins: the integral outer membrane proteins and lipoproteins. 
Outer-membrane proteins such as OmpA, OmpC, OmpF, LamB and PhoE span 
the outer membrane with amphipathic β-strands possessing alternating 
hydrophobic residues. Unlike a typical transmembrane segment comprising a 
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cluster of hydrophobic residues, amphipathic β-strands do not cause the retention 
of proteins in the inner membrane and their insertion into the outer membrane is 
mediated by a dedicated transport system called Bam complex (Pugsley A.P. et 
al., 1993). 
 The other class of membrane proteins includes the lipid-modified proteins, or 
lipoproteins, carrying acyl groups at their N-terminus. Such acyl moieties can 
penetrate into the external and internal leaflets of the IM and OM, respectively, 
thus anchoring lipoproteins to the membranes. Escherichia coli possesses more 
than 90 lipoproteins, most of which are located in the outer membrane facing the 
periplasm, the others being anchored to the inner membrane (Kovacs-Simon A. 
et al., 2011). Because of the extremely hydrophobic property of the lipid moiety, 
the release of lipoproteins from IM and destined to the inner leaflet of OM does 
not occur spontaneously. Instead, it involves the Lol system, which removes 
lipoproteins from the IM, transports them through the periplasmic space, and 
finally targets them to the OM.  
It has to be pointed that in some gram-negative species, but not in E. coli, 
lipoproteins anchored to the OM do not face the periplasm but rather protrude out 
of the surface. As described below, the mechanism responsible for surface 
exposition of lipoproteins is not completely understood (Narita S. et al., 2004) and 
the attempt to elucidate such mechanism is the main objective of this thesis 
project. 
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1.2 Biogenesis of bacterial lipoproteins  
Bacterial lipoproteins of both gram-positive and gram-negative bacteria are 
initially synthesized as preprolipoproteins in the cytosol carrying a LP similar to 
the signal peptides of other secreted proteins (Inouye S. et al., 1977). However, 
the LP of lipoproteins is characterized by a specific conserved sequence at its C-
terminal region, Leu-(Ala/Ser)-(Gly-Ala)-Cys, called lipobox (Kovacs-Simon A. et 
al., 2011) (Hutchings  M.I. et al., 2008)  (figure 2).  
 
 
FIGURE 2 - Schematic representation of lipoproteins. Arrows indicates the cleavage site 
of the leader peptidase 
 
 
This LP can be recognized by either Sec or Tat system and lipoprotein precursors  
cross the cytoplasmic membrane as described above (Hutchings  M.I. et al., 
2008) Processing of preprolipoproteins into their mature forms takes place on the 
periplasmic side of the inner membrane (Okuda S. et al., 2011) (figure 3 a). The 
thiol group on the side chain of the cysteine residue is modified by the covalent 
attachment of a diacylglycerol moiety by a transferase enzyme (Lgt), generating a 
prolipoprotein (Babu M.M. et al., 2006) (figure 3 b). After lipidation, a peptidase 
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(LspA) cleaves the LP of the lipidated prolipoprotein and the lipobox cysteine 
becomes the amino-terminal residue of mature lipoproteins (Tokunaga M. et al., 
1982) (figure 3 c). 
 
 
FIGURE 3 - Lipoproteins maturation process-a) Lipoproteins are synthesized in the cytosol 
as a preprolipoprotein. b) After traslocation across the inner membrane by Sec or Tat pathway, 
the enzyme Ltg forms a thioether linkage between N-terminal Cys and diacylglycerol. c) Lspa 
enzyme cleaves the signal peptide of the prolipoprotein, d) The N-terminal Cys residue is acylated 
by Lnt enzyme. e) The mature lipoprotein can reach the final localization (Okuda S. et al., 2011). 
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In gram-negative bacteria another event occurs: the attachment of an amide-
linked acyl group to the N terminal cysteine residue by a transacylase enzyme 
(Lnt), forming the mature lipoprotein (Kovacs-Simon A. et al., 2011) (figure 3 d). 
Both the diacylglyceryl group and the amino-terminal acyl group participate to the 
anchoring of the lipoprotein to the membrane (Hantke K. et al., 1973) (figure 3 e). 
 
 
         1.3 Difference in lipoprotein localization between E. coli and N. meningitidis 
In many gram-negative bacteria, such as E. coli, mature lipoproteins are localized 
either in the outer leaflet of IM or in the inner leaflet of OM. Transport of 
lipoproteins from the IM to the OM is mediated by the lipoprotein localization 
machinery (Lol) (Tokuda H. 2009). However, in pathogenic spirochetes (Schulze 
R.J. et al., 2006) and N. meningitidis (Bos M.P. et al., 2007) mature lipoproteins 
reach the outer leaflet of OM by a process that remains to be fully elucidated.  
 
 Lipoprotein sorting mechanism in E. coli: the Lol system 
 
Once the lipoproteins are acylated as described above they have two destinies: 
either they are retained in the IM or they are transported to the OM. The final 
destination of lipoproteins depends on the amino acids flanking the lipidated 
cysteine in the mature protein (Bos M.P. et al., 2007). Studies in E. coli have 
demonstrated that the presence at position +2 of an aspartic acid residue 
prevents lipoproteins from binding to the Lol machinery and therefore this amino 
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acid represents a critical IM retention signal. Aspartic acid replacement with a 
serine residue results in Lol-dependent lipoprotein translocation to the outer 
membrane (Seydel A. et al., 1999). More recently, the importance of amino acid 
residues at positions +3 and +4 (Tokuda H. et al., 2004) has also been reported: 
for example lysine is able to weaken the inner membrane retention whereas 
aspartate or glutamate are able to fortify the retention signal (Seydel A. et al., 
1999). 
In the absence of retention signals lipoproteins move to the OM. Since the 
periplasmic space is hydrophilic, lipoproteins must be solubilized to jump from IM 
to OM. Indeed, lipoproteins are not detected in the periplasm under normal 
conditions (Tokuda H. 2009). 
As said above, lipoprotein trafficking is mediated by the Lol system, consisting in 
a transmembrane protein complex (LolCDE), an ATP-binding cassette (ABC) 
transporter, a periplasmic chaperone (LolA) and an outer-membrane receptor 
(LolB) (Tokuda H. 2009). 
The LolCDE complex represents the IM lipoprotein-releasing factor. This three-
protein complex is localized in the inner membrane and has similarities with ATP-
binding cassettes (ABC) (Yakushi T. et al., 2000). LolC and LolE are integral 
membrane proteins (figure 4 b), while LolD is an ABC ATPase (figure 4 a). 
LolCDE is a unique ABC transporter in that it does not catalyze the 
transmembrane transport of substrates but rather releases substrates from the 
outer leaflet of the inner membrane. 
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The release of lipoproteins from LolCDE complex is mediated by LolA. LolA, a 
protein essential for cell viability (Matsuyama S. et al., 1995), is a lipoprotein-
specific molecular chaperone, which forms a soluble one-to-one complex with 
lipoproteins (Matsuyama S. et al., 1997) (Tajima T. et al., 1998) (figure 4 c). LolA 
has an unclosed β-barrel and a lid composed of three α-helices, together 
constituting a hydrophobic cavity that is able to accept the lipid moiety of 
lipoproteins. Energy seems to be needed to disrupt the hydrogen bonds and 
promote the formation of the LolA-lipoprotein complex and the stability of the 
LolA-lipoprotein complex is increased relative to that of the free form of LolA.  
The outer-membrane protein LolB, is the factor able to receive lipoproteins from 
LolA (Matsuyama S. et al., 1997) (Yakushi T. et al., 1998). LolB is itself a 
lipoprotein and is anchored to the outer membrane (figure 4 d).  
Transfer of lipoproteins from LolA to LolB occurs in the absence of energy and is 
presumably driven by the difference in affinity for lipoproteins between LolA and 
LolB  (Yakushi T. et al., 1998). LolB then transfers lipoproteins to the inner leaflet 
of the outer membrane through a currently unknown mechanism (figure 4 e). 
Although the sequence similarity between LolA and LolB is low, the overall 
structure of LolB is very similar to that of LolA and it has a hydrophobic cavity that 
seems to be the binding site for the lipid moieties of lipoproteins (Narita S. et al., 
2004).   
The five LolA-E proteins are all well conserved in gram-negative bacteria, 
indicating that lipoprotein transport is an essential biological process.  
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FIGURE 4 – Schematic representation of the Lol-mediated lipoprotein trafficking 
a-b) Lol CDE is lipoprotein-releasing factor and it is an ATP-binding cassette (ABC) transporter. c) 
The LolA-lipoprotein is an intermediate during lipoprotein transfer to the outer membrane (Yakushi 
T. et al., 1998) able to interact with an ABC transporter called LolCDE. d) The outer-membrane 
LolB protein, is the factor able to receive lipoproteins. e) LolB then transfers lipoproteins to the 
inner leaflet of the outer membrane through a currently unknown mechanism (Matsuyama S. et 
al., 1997). 
 
 Lipoprotein sorting mechanism in Neisseria meningitidis 
 
While in E. coli all known lipoproteins face the periplasm (Tokuda H. 2009), in 
some gram-negative bacteria, including pathogenic spirochetes (Schulze R.J. et 
al., 2006) and Neisseria meningitidis, lipoproteins are present on the outer leaflet 
of the OM (Bos M.P. et al., 2007) (figure 5). Little is known about the exact 
mechanism of lipoprotein translocation across the outer membrane. The 
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spirochete Borrelia burgdorferi lacks a complete Lol system and it has been 
postulated that this may be one of the reasons why several lipoproteins are 
localized in the outer leaflet of the outer membrane of this bacterium (Schulze 
R.J. et al., 2006). More recently, work on lipoproteins of Borrelia has led to the 
proposal that translocation to the outer membrane is mediated by specific 
signatures (Schulze R.J. et al., 2006). A recent study used nuclear magnetic 
resonance (NMR) to demonstrate that the amino terminus of the Neisseria 
meningitidis lipoprotein, fHbp, serves as an extended linker to display the protein 
at the extracellular surface (Mascioni A. et al., 2009 J Biol Chem) (Mascioni A., et 
al.,2009 Biochim et Biophysica Acta). Finally, the existence in N. meningitidis of a 
“flippase” working in a similar manner as the LPS flippase has been postulated. 
However, such enzyme has not been discovered yet and it is not known whether 
specific structural signatures of lipoproteins are required to promote their flippase-
mediated transport.  
 
 
FIGURE 5 - Schematic representation of the difference in lipoprotein sorting between E. 
coli and N. meningitidis  
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         Aim of the project 
 
This research project has two main objectives: 1) understanding of the sorting 
mechanisms of lipoproteins, and 2) development of a lipoprotein-based system to 
deliver foreign proteins to the surface of bacterial cells. 
E coli does not expose lipoproteins to the surface of OM while Neisseria 
meningitidis does. There are two possible explanations for this functional 
difference. One explanation is that N. meningitidis has a specific transport system 
responsible for the traslocation of lipoproteins once they reach the inner leaflet of 
the OM. Alternatively, translocation could be due to specific structural properties 
embedded in N. meningitidis lipoproteins and absent in lipoproteins from E. coli. 
In order to establish which of the two mechanisms plays a major role in surface 
exposition of lipoproteins, two N. meningitidis lipoproteins have been expressed 
in E. coli and their fate in cellular compartmentalization has been analyzed. The 
rationale behind this strategy is that if the export properties are “encoded” in the 
sequence/structure of lipoproteins, the two selected proteins are expected to be 
surface-localized in E. coli as well. If, on the other hand, a translocation 
machinery is involved, the two proteins should be retained in the inner side of 
OM. In this case a shotgun cloning of N. meningitidis genes in E. coli expressing 
the two proteins could be used as a tool to identify the gene(s) of the transport 
system. 
The second aim of the project is to investigate whether surface-exposed 
lipoproteins can be exploited as vehicles to bring heterologous proteins to the 
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bacterial surface. To this aim, specific heterologous proteins are selected, fused 
to N. meningitidis lipoproteins and their compartmentalization investigated.  
23 
 
2) RESULTS 
2.1 Lipoprotein selection 
Factor H binding protein (fHbp) and Neisseria heparin binding antigen (NHBA) 
are both surface-exposed lipoproteins from Neisseria meningitidis originally 
identified by reverse vaccinology (Delany I. et al., 2013) (Serruto D. et al., 2012). 
They are included in a multicomponent vaccine against Serogroup B Neisseria 
meningitidis recently registered in Europe (Serruto D. et al., 2012). fHbp is an 
important virulence factor enabling the meningococcus to evade the complement 
system (Piet J.R. et al., 2012). NHBA structure consists of an 8-strand β-barrel 
that closely resembles the C-terminal domains of fHbp and of transferrin-binding 
protein B (Serruto D. et al., 2012). This common fold, together with additional 
structural similarities, suggests a common ancestor for these important antigens 
and a role of the β-barrel fold in inducing immunogenicity against N. meningitidis 
(Esposito V. et al., 2011).  
 
 
2.1.1_Neisseria meningitidis factor H binding protein  
Factor H binding protein (fHbp) is a 28 kDa surface-exposed lipoprotein of 
Neisseria meningitidis (Cantini F. et al., 2005). fHbp is able to bind human 
complement factor H (fH), the central regulator of the alternative complement 
pathway (Cendron L. et al., 2011), and in this way it down-regulates complement 
activation (Lo H. et al., 2009). The interaction between fHbp and human Factor H 
prevents complement-mediated lysis (Madico G. et al., 2006; Schneider M.C. et 
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al., 2009). fHbp is present on the surface of all meningococcal strains (Fletcher 
L.D. et al., 2004) and high levels of fHbp expression have been found in hyper-
virulent meningococcal strains (Schneider M.C. et al., 2009). 
 
 
 
FIGURE 6 - 3D of fHbp binding to human Factor H - The short consensus repeat region 6 
(SCR6) of Factor H is mostly the site bound by fHbp. Binding was mediated by charged amino 
acid residues in the fHbp structure, which mimicked portions of sugar molecules that were 
previously identified to bind to fH SCR 6. (Based on coordinates published by Schneider M.C. et 
al., 2009) (McNeil L.K. et al., 2013) 
 
 
fHbp is synthesized as a precursor carrying at its N- terminal,  a canonical  signal 
peptide of 19 amino acids including a lipobox. Like all lipoproteins, the first amino 
acid of matured fHbp is a cysteine. 
Structural studies have shown that fHbp is organized in three domains, called A, 
B, C (Cantini F. et al., 2005). Domain A encompasses amino acid 27 to 119, 
Domain B starts from amino acid 120 and ends at residue 183, and finally 
Domain C spans from amino acid 184 to the C-terminal end (amino acid 274) 
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(figure 7). The protein  structure consists of eight-stranded antiparallel β-barrel 
(157-274) topped by a single α-helix (157-160) and a flexible tail (120-156), which 
links  Domain A to Domain B (Cantini F. et al., 2006) (figure 7). The Factor H 
binding site is located in Domain A and it has been shown that a single amino 
acid replacement (R41S) is sufficient to impair fH binding (Beernink P.T. et al., 
2012). 
 
                                                                                                                                        
FIGURE 7 – Structural organization of Domains B and C of fHbp.  a) Amino acid sequence 
of fHbp. Location of  β-barrels and α-helix are highlighted in colors and schematized under the 
sequence. b) The crystal structure of domains B and C have been characterized and the analysis 
showed the presence of eight-stranded antiparallel β-barrel topped by a single α-helix and a 
flexible tail (Beernink P.T. et al., 2012). 
 
 
2.1.2_Neisseria Heparin Binding antigen (NHBA) 
 Neisseria meningitidis heparin-binding antigen (NHBA) is a 49-kDa surface-
exposed lipoprotein. Its amino acid sequence carries an arginine-rich region 
responsible for heparin binding, which correlates with an increased survival of N. 
meningitidis in human serum (Serruto D. et al., 2010). The 3D structure of the C-
terminal domain of NHBA has been solved. This domain independently folds and 
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is organized in an 8-strand β-barrel, resembling the very well characterized C-
terminal domains of N. meningitidis fHbp (figure 8). As already pointed out, these 
structure similarities suggest a common ancestor for these important antigens 
(Esposito V. et al., 2011). 
 
FIGURE 8 - Crystal structure of Neisseria meningitidis heparin binding antigen (Esposito 
V. et al., 2011). 
 
 
2.2 Expression of fHbp and NHBA in E. coli  
fHbp and NHBA genes were amplified by PCR from N. meningitidis strain MC58 
and the amplification products were cloned into the pET21b plasmid,  by using 
the PIPE method (Klock H.E. et al,. 2009). The derived pET21_fHbp and 
pET21_NHBA plasmids were used to transform BL21D3(ompA) strain, obtaining 
the recombinant strains (pET21_fHbp)BL21D3(ompA) and 
(pET21_NHBA)BL21D3(ompA). Both strains were grown at mid-log phase and 
then antigen expression was induced for two hours by addition of 1mM IPTG (as 
described in Materials and Methods). Figure 9 shows the SDS-polyacrilamide gel 
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electrophoresis (SDS-PAGE) of total lysates before and after IPTG induction. 
fHpb appeared to be well expressed in E. coli, as indicated by the presence of a 
new protein band with the expected molecular mass in the cell extracts from 
induced cultures (figure 9 a). As far as NHBA protein is concerned, its expression 
could not be clearly deduced from the SDS-PAGE because of its co-migration 
with endogenous protein species. However, an intensification of a specific band 
suggested that NHBA was also successfully expressed, even though at a level 
inferior to the one of fHbp (Figure 9 b). These conclusions were corroborated by 
Western Blot analysis using anti-fHbp and anti-NHBA specific antibodies (Figure 
10 a and 10 b, first two lanes). Interestingly, for both proteins two bands were 
visible, the ones of higher molecular mass are likely to correspond to the protein 
precursors still carrying the LP.  
 
FIGURE 9 - Expression of fHbp and NHBA antigens in E.coli. a) SDS-PAGE of total cell 
extracts of E. coli BL21 ompA strain expressing fHbp shows a clear expression after induction of 
lipoprotein. The lighter band represents prolipoprotein form, that could be located both in 
cytoplasm or on the inner membrane (Kovacs-Simon A. et al., 2011); the heavier band 
corresponding to mature form (Inouye S. et al., 1977). Both of them are boxed.  b) SDS-PAGE of 
total cell extracts of E. coli BL21 ompA strain expressing NHBA shows weak lipoprotein 
expression after induction. The feeble band is boxed. 
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          2.3 Cellular compartmentalization of fHbp and NHBA in E. coli  
We next investigated whether fHbp and NHBA reached the outer membrane of E. 
coli. To address this question we took advantage of the property of 
BL21D3(ompA) to release Outer Membrane Vesicles (OMVs) in the culture 
supernatant. OMVs are small spherical particles 20-250 nm in diameter 
constitutively secreted by all gram-negative bacteria as a result of a “budding out” 
process of the outer membrane (Klock H. et al., 2009). Since OMVs are 
constituted by OM (LPS, OM proteins and lipids), peptidoglycan and periplasmic 
proteins, (Ellis T.N. et al., 2010), if fHbp and NHBA were expressed either 
intracellularly or anchored to the inner membrane, they should not be found in 
OMVs. On the other hand, if the two proteins are localized in the periplasm or 
attached to the outer membrane they should be part of the OMV proteome.  
OMVs were purified from the supernatants of (pET21_fHbp)BL21D3(ompA) and 
(pET21_NHBA)BL21D3 (ompA) cultures after 2 hour induction with IPTG. 
Culture supernatants were collected by centrifugation at 5.000 x g for 15 minutes 
and subjected to a final step of ultracentrifugation (see Materials and Methods). 
Pellets containing OMVs were analyzed by Western Blot using the fHbp or NHBA 
specific polyclonal antibodies. As a negative control, OMVs purified from E. coli 
BL21(ompA) transformed with pET21 empty vector were used. As shown in 
figure 10, both fHbp and NHBA proteins were found in OMVs. Interestingly, only 
the lower molecular mass band of fHpb reached the OMVs, supporting the 
hypothesis that the other band represents the protein precursor still carrying the 
LP. Less clear is the situation for NHBA for which two immune-reactive bands 
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were visible in OMVs, the lower band having the expected molecular mass of the 
mature form. 
 
 
FIGURE 10 - fHbp full length and NHBA expression in total extracts and OMVs evaluated 
by Western Blot analysis- a) Double band corresponding both to the precursor and mature 
lipoprotein in bacterial cells can be compared to mature form presented in a single band in OMVs 
(Inouye S. et al., 1977) (Kovacs-Simon A. et al., 2011). b) NHBA expression is evident in both 
total lysates and OMVs even if the different number of bands cannot be appreciated.  
 
  
Finally, we investigated whether the two proteins were exposed on the surface of 
E. coli, as it occurs in N. meningitidis, or rather they remained anchored to the 
internal leaflet of OM. To address this question we used two experimental 
approaches. The first approach consisted in the “shaving” of purified OMVs with 
proteinase K. The proteolytic treatment removes all proteins protruding out of the 
OMV surface while the luminal compartment is protected. As shown in Figure 11, 
fHbp was completely digested by proteinase K treatment indicating that the 
protein was exposed on the OMV surface. On the contrary, NHBA digestion 
occurred only upon SDS treatment of OMVs.   
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FIGURE 11 - Analysis of antigens localization and orientation in OMVs- Purified OMVs 
expressing the heterologous protein were incubated with and without Proteinase K for 10 min at 
37°C in the presence or absence of a pre-treatment with 1% SDS to destroy OMV integrity. Data 
indicate the fHbp localization on the outer membrane of OMVs and orientation to the external 
environment (a). The mbp-control shows the integrity of the OMVs (a1). The NHBA protein signal 
is still present after treatment with protease: this is an evidence of the non-digestion of NHBA (b). 
The protection conferred by the presence of the outer membrane makes possible hypothesize the 
localization of NHBA in the periplasm or anchored to the OM but oriented to the lumen of OMVs. 
 
 
To confirm the external localization of fHbp, Fluorescence Activated Cell Sorting 
(FACS) analysis was performed on (pET21_fHbp)BL21D3 (ompA) strain and on 
(pET21)BL21D3 (ompA) strain as control using anti-fHbp antibodies (Figure 12).  
Cultures were grown to OD600= 0.5 and subsequently induced by addition of 1mM 
IPTG. Cells from 1 ml of each culture were collected by centrifugation at 10.000 x 
g for 5 min at 4°C, and pellets were re-suspended in PBS to obtain a suspension 
of  2x107/ml cells. Cells (50 µl) were dispensed in 96-well plate with round bottom 
31 
 
and three different concentrations of anti-fHbp polyclonal antibodies were added 
followed by incubation with a secondary antibody labeled with FITC (see Material 
and Methods). Finally cells were re-suspended in 4% formalin and analyzed by 
FACS. As shown in Figure 13, anti-fHbp antibodies specifically recognized 
(pET21_fHbp)BL21D3 (ompA) cells, confirms the results obtained by Proteinase 
K treatment of OMVs.  
 
FIGURE 12 - The evidence of the external orientation of fHbp confirmed by Fluorescence 
Activating Cell Sorting analysis_ Bacteria cells were analyzed by FACS using the antigen-
specific polyclonal antibody. Peaks that came out from the ∆ompA pET21empty vector strain 
labeled with fluorescein isothiocyanate (a) were compared to those produced by ∆ompA 
expressing fHbp strain (b) at the same concentration. The overlapping of the two cell populations 
(c) shows an evident shift of the peaks corresponding to the strain able to express the lipoprotein. 
 
 
         2.4_Quantification of fHbp in OMVs 
Finally, we investigated the amount of fHbp present in OMVs. Such quantification 
was carried out using Western Blot analysis. Increasing amounts of OMVs were 
separated by SDS-PAGE together with different amount of purified recombinant 
fHbp. After separation, proteins were transferred to nitrocellulose filter by electro-
blotting and stained with anti-fHbp antibodies. As shown in Figure 13, 0.5 g of 
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OMVs extracted proteins carried approximately 100 ng of fHbp, corresponding to 
approximately 20% of total OMV proteins. 
 
FIGURE 13 – Quantification of OMV-associated fHbp by Western Blot - Different quantities 
of purified recombinant protein and OMVs expressing fHbp were separated by SDS-PAGE, 
transferred to nitrocellulose filters and incubated with fHbp-specific antibodies. From the 
comparison of band intensities it was estimated that 1 g of OMV carries approximately 200 ng of 
fHbp, corresponding to 20% of total OMV proteins. 
 
 
2.5 Elucidation of structural features promoting fHbp exposition on 
bacterial surface  
The results described above indicate that fHbp, but not NHBA, reaches the 
surface of E. coli, the same way it does in N. meningitidis. This interesting 
observation leads to the hypothesis that the “flipping out” mechanism, which 
mediates the transfer of lipoproteins from the inner leaflet of OM to the external 
LPS-containing leaflet, does not require the intervention of specific transport 
systems but rather is dependent on the presence of structural signatures 
embedded in lipoproteins. The data also suggest that such signatures can differ 
from lipoprotein to lipoprotein and are not universally recognized by all gram-
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negative species, thus giving an explanation why NHBA  is not surface-localized 
when expressed in E. coli. 
In the attempt to shed light on the structural signatures that might be involved in 
promoting the transfer of fHbp to the bacterial surface, we created a number of 
fHbp mutations and we investigated in which way such mutations could affect 
fHbp translocation. 
 
 
 
FIGURE 14 – Schematic representation of fHbp structural organization 
 
 
We first focused our attention to the fHbp region immediately adjacent to the N-
terminal acylated cysteine.  The sequence analysis of this region reveals the 
presence of a stretch of four glycine residues. Such glycine-rich box is relatively 
conserved in lipoproteins, as deduced from the sequence analysis of different 
gram negative lipoproteins (figure 15).  
To test whether the glycine residues are involved in the translocation process, 
two different mutated forms of fHbp were created (figure 16). In one mutant, the 
four glycine residues were removed, while in the second mutant the four glycine 
residues were replaced with alanine. 
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FIGURE 15- Schematic list of lipoproteins with conserved region glycine stretch 
 
 
In order to generate both fHbp mutants, pET21_fHbp wt plasmid was used as 
template of a PCR-mediated site-directed mutagenesis (see Materials and 
Methods for details). The resulting pET21_fHbp∆GLY4 and 
pET21_fHbpGLY4>ALA4 plasmids were used to transform E. coli BL21(ompA) 
strain. The derived strains were grown at mid-log phase and then fHbp∆GLY4 and 
fHbpGLY4>ALA4 expression was induced for two hours by addition of 1mM IPTG. 
Before and after IPTG addition bacterial cells from 1 ml culture were collected by 
centrifugation and analyzed by SDS-PAGE. Furthermore, OMVs were purified 
from culture supernatants after IPTG induction (see Materials and Methods for 
details of OMV purification).  As shown in figure 17 a-b, both fHbp∆GLY4 and 
fHbpGLY4>ALA4 were expressed to a similar level with respect to the wild type 
protein and were compartmentalized in OMVs. Also similarly to what observed in 
wild type fHbp, two protein species were present in total extracts, while OMVs  
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FIGURE 16 – Schematic representation of the fHbp mutants targeting the four N-terminal 
glycine residues 
 
 
carried a single species, most likely representing the processed, LP-less mature 
forms.  
Having demonstrated that both mutant forms of fHbp were expressed and 
reached the OMVs, we next asked the question whether the mutations have 
somehow affected their compartmentalization in the membrane. To this aim, the 
Proteinase K assay was performed, in which OMVs expressing fHbp∆GLY4 and 
fHbpGLY4>ALA4 were treated with protease in presence or absence of SDS and 
then analyzed by Western Blot. As shown in Figure 18, neither the removal of the  
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Figure 17 - Western Blot analysis of fHbp∆GLY4 and fHbpGLY4>ALA4 expression in 
bacterial total lysates and OMVs –  
 
 
glycine stretch nor its replacement with the four alanine residues prevented fHbp 
from being exposed on the surface of OMVs, indicating that despite its 
conservation this motif is not involved in lipoprotein flipping out mechanism.  
 
 
 
FIGURE 18 – Localization of fHbp∆GLY4 and fHbpGLY4>ALA4 in OMVs. The Proteinase K 
assay in the presence or absence of detergent was used to establish protein 
compartmentalization. See Text for details. 
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We next focused our attention on the three structural domains in which fHbp 
protein is organized. As already anticipated (see also Figures 7 and 14), the 3D 
structure of fHbp has revealed that the protein is composed of three main 
structural domains that have been previously shown to fold independently when 
expressed separately in E. coli (Giuliani M.M. et al., 2004). The main question we 
wanted to address was whether any of these domains was specifically involved in 
the flipping out process. To answer this question, the three fHbp mutants 
depicted in Figure 19 were generated. In one mutant the C-terminal C domain 
was removed, while in a second mutant both B and C domains were 
simultaneously eliminated. As far as the third mutant is concerned, domain A and 
B were deleted so that the C domain was juxtaposed next to the glycine stretch. 
The three mutants were generated using the same approach described for the 
construction of   fHbp∆GLY4 and fHbpGLY4>ALA4 (Klock H. et al., 2009).  The 
three derived plasmids carrying the mutated forms of fHbp, pET21_fHbpA, 
pET21_fHbpA-B, pET21_fHbpC, were used to transform E.coli ompA strain. 
The resulting strains were grown at mid-log phase and then fHbpA, fHbpA-B and 
fHbpC expression was induced for two hours by addition of 1mM IPTG. Total cell 
extracts of bacterial cells were prepared by collecting cells from 1 ml culture and 
by re-suspended the cell pellets directly in SDS-PAGE sample loading buffer. 
Figure 20 shows the Western Blot analysis of total extracts of the recombinant 
strains expressing the three fHbp mutants. fHbpA and fHbpA-B were both 
expressed even though the amount of proteins appeared to be lower than what 
observed in the lysate of the strain expressing the full length fHbp (figure 20 a-b).  
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FIGURE 19 – Schematic representation of the fHbp domain deletion mutants  
 
 
By contrast, no immune-reactive band corresponding to the domain C fused to 
the LP could be observed, suggesting that the protein was not expressed (figure 
20 c). It has to be pointed out that the polyclonal antibodies used in Western Blot 
were raised against the whole fHbp and therefore it cannot be excluded that 
domain C is poorly recognized by these antibodies. Antibodies specificity with 
respect to the different fHbp domains should also be taken into account before 
drawing conclusions on the level of expression of fHbpA and fHbpA-B with 
respect to the wild type protein.  
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To evaluate the expression and localization in OMVs of fHbpA and fHbpA-B, 
Proteinase K assay was carried out. As shown in figure 21, fHbpA-B and at least 
 
FIGURE 20 - Expression of fHbpA, fHbpA-B and fHbpC in E. coli total cell extracts. 
 
 
partially fHbpA were digested by protease treatment even in the absence of 
detergent. This result strongly suggests that both deleted proteins still carry the 
structural signatures required for the flipping out mechanism and such signatures 
reside, at least in part, in the N-terminal A domain. 
 
FIGURE 21 - Expression and localization analysis of fHbpA and fHbpAB in OMVs- The 
Protease K assay described in Figure 18 was used for the analysis of protein 
compartmentalization. The digestion of the periplasmic maltose binding protein was followed as 
control. 
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         2.6  fHbp as delivery system of heterologous proteins to bacterial surface 
In addition to shed light on the mechanisms of lipoprotein transport in bacteria, 
the data reported above might pave the way to potentially interesting 
biotechnological applications.  
The ability to decorate the bacterial surface with heterologous proteins has been 
the object of intense investigation (Chen W et al., 2002) (Georgiou G. et al., 
1997)(Lee S.Y. et al., 2003) (Pozzi G. et al., 1992) (Nguyen T.N. et al., 1993). 
Several applications can be envisaged, including the possibility to develop 
bioreactors which carry out important chemical reactions catalyzed by surface 
associated enzymes, and to create bacteria with novel immunogenicity properties 
for vaccine applications.  
A number of surface delivery systems have been already described, many of 
them exploiting the capacity of proteins naturally destined to the surface (“carrier 
proteins (CPs)”) to act as chaperones of heterologous proteins (“passenger 
proteins (PPs)”) (Wentzel A. et al., 2001). PPs are fused either to the N-terminus 
or to the C-terminus of CPs so that they can reach, and get anchored to, the cell 
surface. Although the strategy has been successfully applied in several cases, 
CPs do not work universally and the optimal CP required for efficient 
translocation of  a specific PP cannot be predicted a priori. For these reasons, 
there is a need of novel CPs capable of exporting otherwise recalcitrant proteins. 
On the basis of the above considerations we decided to test whether fHbp could 
be exploited as a delivery system for hererologous antigens in E. coli. We 
focused our attentions on three promising vaccine candidates: the backbone 
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protein of pili from Group B Streptococcus (GBS), the iron transport protein 
FhuD2  and Protein A, both from Staphylococcus aureus.   
 
 fHbp-mediated membrane delivery of GBS59 pilus backbone protein 
 
GBS is a Gram-positive pathogen that causes life-threatening pneumonia, sepsis, 
and meningitis in newborn and young infants (Johri A.K. et al., 2006) (Dramsi S. 
et al., 2006) Indeed, GBS is responsible for over 80% of all bacterial infections in 
infants below four months of age. Because children delivered from women with 
high titers of anti-GBS opsonophagocytic antibodies, are protected from GBS 
infections (Baker C.J. et al., 1976) (Lin F.Y. et al., 2004) (Maione D. et al., 2005), 
vaccination of women in childbearing age or pregnant women appears to be the 
ideal long-term solution to newborn infections.  
Although major efforts have been made in the development of multivalent 
capsular conjugate vaccines, currently there is no vaccine against GBS. To 
overcome serotype-specific immunity and the increasing number of non-typeable 
isolates, vaccines based on conserved protective proteins are highly desirable. 
The most promising protein-based vaccine candidates selected so far are the 
structural subunits of pili that are long filamentous structures protruding from the 
bacterial surface (Nuccitelli A. et al., 2011). Pili are constituted by three structural 
proteins, one of which, the backbone protein (BP), is highly protective. Extensive 
analysis of a large panel of GBS isolates has revealed the existence of eight non-
cross-protective BP variants (Margarit I. et al., 2009). Although they differ in 
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amino acid sequence, their 3D structure is conserved, being organized in four 
structural domains (Nuccitelli A. et al., 2011). Interestingly, one of these domains, 
domain D3, is immunologically relevant and the target of most functional 
antibodies (Nuccitelli A. et al., 2011).  
We decided to create two chimeric proteins in which Domain 3 of GBS59, the 
backbone protein of pilus variant 2b, was fused to either full length fHbp or to 
fHbp Domain A (fHbpA).   
 
 
 
FIGURE 22 - 3D structure of GBS59 pilus protein from Streptococus agalactiae. The 
small immunogenic Domain 3 of the protein is boxed in yellow. (Nuccitelli A. et al., 2011) 
 
 
GBS59 Domain 3 coding sequence was amplified by PCR from chromosomal 
DNA of  Streptococcus agalactiae strain 515 and the amplified product was 
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inserted into pET21_fHbp and pET21_fHbpA  plasmids (Figure 23) using the 
PIPE method (Klock H. et al., 2009).  
The derived recombinant plasmids pET21_fHbp-GBS-Dom3 and  pET21_fHbpA-
GBS-Dom3 plasmids were used to transform E.coli BL21(DE3) ompA strain. 
 
 
 
FIGURE 23 - Schematic representation of the two fHbp chimeric proteins carrying 
Domain 3 of GBS59 pilus backbone protein. 
 
 
The resulting strains were grown in LB at mid-log phase and then antigens 
expression was induced for two hours by addition of 1mM IPTG. Before and after 
induction, 1 ml of culture was collected and bacterial total lysates were prepared 
by re-suspending bacterial cells in SDS-PAGE sample buffer. Aliquots of total 
lysates were run on SDS-polyacrylamide gel and transferred to nitrocellulose filter 
for Western Blot analysis using anti-GBS59 antibodies. As shown in Figure 24, 
both fusion proteins were expressed, as indicated by the appearance of two 
immune-reactive bands in cell extracts. The reason why two protein species were 
resolved on the gel remains to be experimentally investigated. One possible 
explanation is that both chimeras are cleaved by an endogenous protease at a 
specific position either at the N-terminus of the fusions or within the GBS59 D3 
domain.  
44 
 
Having demonstrated that the fusions expressed in E. coli, we asked the question 
whether the proteins reached the outer membrane and were eventually exposed 
on the bacterial surface. To address this question, once again, we exploited the 
OMV overproducing phenotype of the strains. After 2 hours induction with IPTG, 
OMVs were purified from the culture supernatants and analyzed by Western Blot.  
As shown in figure 25 a-b, both recombinant proteins could reach the vesicular 
compartment, indicating fHbp and fHbpA could work as PP for GBS59Dom3. 
 
 
FIGURE 24 - Expression and compartmentalization of fHbp-GBS59Dom3 and fHbpA-
GBS59Dom3 chimeras in E. coli – Aliquots of total cell extracts and OMVs from recombinant 
E.coli BL21(DE3) ompA  strains expressing fHpb-GBS59Dom3 and fHbpA-GBS59Dom3 were 
analyzed by Western Blot using GBS59Dom3-specific antibodies  
 
 
To analyze the localization of the chimeras in OMVs we treated the recombinant 
OMVs with Proteinase K in the presence or absence of detergent and we 
subsequently analyzed the samples by Western Blot. The results of this 
experiment indicate that both proteins were at least partially exposed on the OMV 
surface in that a fraction of the chimeric proteins was digested even in the 
absence of SDS (Figure 25). 
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FIGURE 25 – Analysis of localization of fHbp-GBS59Dom3 and fHbpA-GBS59Dom3 in 
OMVs -OMVs were purified from the culture supernatants of  E.coli BL21(DE3) ompA  strains 
expressing fHpb-GBS59Dom3 and fHbpA-GBS59Dom3 and digested with Proteinase K in the 
presence or absence of 1% SDS. After digestion, the samples were analyzed by Western Blot 
using a GBS59Dom3-specific antibodies. As control of the integrity of  the OMVs in the absence 
of detergent, aliquots of OMVs carrying fHbpA-GBS59Dom3 were also analyzed by Western Blot 
using polyclonal antibodies against MBP, a protein present in the lumen of OMV. 
 
 
 fHbp-mediated membrane delivery of S. aureus FhuD2 and SpA_DEABC 
 
On the basis of the promising results obtained with GBS59 Domain 3, we asked 
the question whether in addition to GBS59Dom3 other proteins could be 
delivered to the membrane of E. coli using fHbp as chaperone. We focused our 
attention on two S. aureus virulence factors, fhuD2 and Protein A, which have 
been proposed as promising vaccine candidates (Mariotti P. et al., 2013) (Etz H. 
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et al., 2002). fhuD2 is a lipoprotein involved in iron-hydroxamate uptake, 
belonging to the core genome of S. aureus. The protein is highly conserved and 
is expressed in a wide variety of epidemiologically relevant S. aureus strains 
(Mishra R.P.N. et al., 2012) (Mariotti P. et al., 2013). The rationale of using 
FhuD2 as vaccine component  is to induce antibodies that inhibit FhuD2-
mediated iron up-take in S. aureus. In addition, FhuD2- specific antibodies bind to 
the protein naturally localized on the surface of S. aureus, thus mediating 
opsonophagocytosis.  
Protein A is a cell-wall anchored protein expressed in the majority of S. aureus 
isolates and representing the most abundant surface protein of this pathogen. Its 
major function is to bind the Fc domain (and the VH3 domain) of immunoglobulins 
(Sasso E.H. et al., 1989) and in so doing exerts two main effects: from one hand 
it impairs antibody-mediated opsonization and phagocytosis, and on the other 
hand it stimulates apoptosis of B cells by binding to their receptors (Kim H.K. et 
al., 2010) (Forsgren A. et al.,1974) (Goodyear C.S. et al., 2004). The mechanism 
of action of a SpA-based vaccine involves the elicitation of antibodies that 
prevents SpA binding to the immunoglobulin Fc domain, thus avoiding SpA toxic 
activity. In this work we cloned and expressed a particular mutated and truncated 
form of SpA in which the C-terminal domain has been removed and the Fc 
binding motif present in each of the five Ig binding domains was modified to 
prevent Fc binding. When used as vaccine this mutated form is still capable of 
eliciting fully functional neutralizing antibodies (Kim H.K. et al., 2010).   
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FIGURE 26 – 3D structural models of FhuD2 (a)(Mariotti P.et al 2013) and SpA_DEABC (b) 
(Gouda H. et al., 1992) 
 
 
fhuD2 and spa_DEABC coding sequences were amplified from plasmids pET21-
fhuD2 AND pET21-spaDEABC and cloned into plasmids pET21-fHbp and 
pET21fHbpA, respectively by using PIPE method. In so doing, FhuD2 was fused 
to the C- terminus of full length fHbp while Spa_DEABC to the A domain of fHbp 
(Figure 27). 
 
 
FIGURE 27 - Strategies to clone fhuD2 and spaDEABC proteins to C terminal region of 
fHbp full length and fHbp domain A respectively 
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pET21-fHbp-fhuD2 and  pET21-fHbpA-spaDEABC plasmids were used to 
transform E. coli ompA strain. The derived recombinant strains were grown at 
mid-log phase and total cell extracts were prepared from bacteria collected before 
and after IPTG addition. In parallel, OMVs were collected from the supernatants 
of both cultures after IPTG-induced protein expression. Both total cell extracts 
and OMVs preparations were analyzed by Western Blot using anti-FhuD2 and 
anti-SpaDEABC antibodies. As shown in Figure 28, both chimeric proteins were 
not only well expressed but also compartmentalized in the vesicle fraction. 
 
 
FIGURE 28 - fHbp fl+fhuD2 and fHbp A+spaDEABC chimeric protein expression in 
bacterial total lysates and in OMVs tested by Western Blot technique- Bands corresponding 
to the expression of both fusion proteins are evident (b),(c) suggesting an high level of 
expression. 
 
 
Finally we analyzed whether the two proteins were exposed on the surface of the 
outer membrane using the Proteinase K assay already described. As shown in 
Figure 29 chimeric proteins were digested only in the presence of detergent, 
suggesting that they are associated to the outer membrane but oriented toward 
the periplasmic space. 
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FIGURE 29 – Analysis of fHbp-fhuD2 and fHbpA-spaDEABC compartmentalization in 
OMVs- Protease K assay was carried out in the presence and absence of detergent (1% SDS) as 
already reported in Figure 25. 
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3) DISCUSSION 
The two main objectives of this project were 1) to contribute to the understanding 
of the reason why outer membrane-anchored lipoproteins are surface –exposed 
in some bacterial species while in others they face the periplasmic space, and 2) 
to explore the possibility of exploiting surface-exposed lipoproteins as “vehicles” 
to deliver heterologous proteins to the bacterial surface.  
Both objectives have been achieved. 
As far as the mechanism of lipoprotein sorting is concerned, we expressed two N. 
meningitidis lipoproteins, fHbp and NHBA, in E. coli and we asked the question 
whether they could reach the cell surface or rather they were attached to the 
outer membrane but facing the cytoplasmic space. Since in N. meningitidis both 
proteins are surface-exposed, their appearance on the E. coli surface would 
indicate that the final step of lipoprotein sorting involving their “flipping out” from 
the inside to the outside of OM occurs via intrinsic structural properties. On the 
other hand, should the proteins be found inside the cells, it would suggest that 
specific “flippases” are involved in the sorting process.  
The results of our work indicate that specific transport systems are not strictly 
required, at least for some lipoproteins. In fact, fHbp was efficiently transported to 
the surface of E. coli cells. Therefore, at least some lipoproteins, including fHbp, 
carry structural features sufficient to bring them to the bacterial surface.  
However the sorting mechanism appears to be more complicated than expected. 
In fact, NHBA, another lipoprotein that in N. meningitidis protrudes out of the 
surface, is not surface-exposed in E. coli. As already pointed out, to reconcile 
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these apparently contradictory results we postulate that the “flipping out” 
mechanism, which mediates the transfer of lipoproteins from the inner leaflet of 
OM to the external LPS-containing leaflet, does not require the intervention of 
specific transport systems but rather is dependent on the presence of structural 
signatures embedded in lipoproteins. However, such signatures can differ from 
lipoprotein to lipoprotein and are not universally recognized by all gram-negative 
species. 
In an attempt to characterize such signatures we generated a number of 
mutations in fHbp and we followed the effect of such mutations on surface 
compartmentalization.  
Five fHbp mutants were produced. The first two mutants involved the four-glycine 
stretch located immediately downstream from the lipobox. Since such glycine 
stretch is present in other lipoproteins, we tested whether it could play a role in 
lipoprotein sorting. However, neither the deletion of the four glycine residues nor 
their replacement with alanine affected the property of fHbp to reach the E. coli 
surface.   
We next removed specific structural domains of fHbp. The crystal structure of 
fHbp has revealed that the protein is organized in three domains (Domain A, B 
and C), which can fold independently when expressed in E. coli.  We therefore 
generated a mutant deprived of the C-terminal C domain (fHbpAB), and a mutant 
in which both Domain C and B are deleted. Finally, we designed a mutant 
deprived of Domains A and B in which Domain C is directly fused to fHbp LP and 
lipobox. When the expression and location of these mutant proteins was 
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analyzed, we found that Domain C could not be expressed while both fHbpA and 
fHbpAB were surface-associated. From these data two main conclusions could 
be drawn. First, that the C Domain is not involved in fHbp sorting. Second, that 
the A Domain carries most of the “information” needed to deliver fHbp to the OM 
and to expose it to the extracellular milieu.  
Having demonstrated that fHbp (and its Domain A and AB) can travel from the 
cytoplasm where it is synthesized all the way to the bacterial surface even if it is 
expressed in E. coli, we decided to investigate whether fHbp could work as a 
surface chaperone for heterologous  proteins. 
For this study, which represents the second project objective, we focused our 
attention on three protein antigens which are vaccine candidates against two 
important human pathogens, Group B Streptococcus (GBS) and Staphylococcus 
aureus. One protein is the immunogenic D3 domain of GBS59, the main 
component of the pili present in all GBS isolates and representing an important 
virulence factor. It has been previously shown that GBS59 D3 domain induces 
potent opsonophagocytic antibodies which protect mice from GBS lethal 
challenge (Nuccitelli et a.l, 2011). The other two proteins, FhuD2 and a mutated 
form of Protein A, are two S. aureus antigens with protective activity in different 
mouse models. The successful delivery of these antigens to the surface of E. coli 
could pave the way to the development of easy-to-produce multi-valent vaccines. 
The three proteins were fused either to the full length fHbp or to Domain A and 
we investigated whether they could be delivered to the OM and eventually could 
get exposed to the bacterial surface.  
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As far as the first question is concerned, our data clearly show that the chimeric 
proteins can indeed reach the outer membrane. This was demonstrated by 
showing that the proteins could be incorporated into OMVs. This is an important 
achievement since it has been recently shown that OMVs carrying heterologous 
antigens can induce potent, antigen-specific, functional antibodies even if the 
antigens are located in the lumen of OMVs (Fantappiè et al., 2014). In addition, it 
is known that lipoproteins are particularly immunogenic in that their lipid moiety 
exerts an adjuvant effect by interacting with TLR2 of antigen presenting cells 
(APCs) (Hefty et al., 2002). Therefore, although it remains to be experimentally 
demonstrated, because of their being fused to a lipoprotein (fHbp or fHbpA) , 
GBS59, FhuD2 and Spa_DEABC could elicit good immunological responses. 
With respect to the second question as to whether when fused to fHbp or fHbpA 
the three antigens reach the bacterial surface, the data seem to indicate that this 
is not always the case. GBS59 was surface-exposed while the other two proteins 
appear to be predominantly inserted into the OM but facing the periplasmic 
compartment. The reasons why the three proteins behave differently remain to be 
investigated. One possible explanation is that the structural nature of the 
passenger protein plays a role in determining its final destination. However, it has 
to be pointed out that our conclusion on the localization of the three heterologous 
antigens in the OM is based on a single experimental approach, namely the effect 
of Proteinase K treatment of OMVs expressing the three antigens. Other 
confirmatory experiments such as FACS analysis and mass spectrometry would 
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be needed to unequivocally determine the localization and orientation of the 
proteins.   
 
 
Table 1 - Summary of all constructs generated in this study 
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4) CONCLUSIONS 
It is our opinion that the experimental work described in this document brings an 
important contribution to the understanding of the sorting mechanisms of 
lipoproteins in bacteria. Differently from what previously believed, lipoproteins 
have an intrinsic capacity to reach the surface of the outer membrane and they 
appear not to require specific sorting machineries. However, the structural 
signatures that allow lipoproteins to become surface-exposed appear, at least in 
some cases, species-specific in that when expressed in heterologous systems 
some lipoproteins remain anchored to the inner leaflet of the outer membrane. 
This is the case for instance of N. meningitidis NHBA, which, when expressed in 
E. coli, is not surface-exposed. Future work is required to shed light of this 
interesting species-specific process.  
The second important contribution of this experimental work is the discovery that 
fHbp can work as chaperone to expose heterologous proteins on the bacterial 
surface. This observation can lead to numerous industrial applications, from 
biocatalysis to immunotherapy and vaccines. However, not all heterologous 
proteins are properly exposed on the bacterial surface when fused to fHbp. The 
understanding of the structural constrains that determine the final destination of 
chimeras should be the object of future experimental work. 
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 5) MATERIALS AND METHODS 
5.1_Bacterial strains and culture conditions 
E. coli strains BL21-(DE3) and HK-100 (Table 3) were routinely grown in LB broth 
at 37°C and used for cloning and expression experiments, respectively. Stock 
preparations of strains in LB + 15% glycerol were stored at -80°C. Each bacterial 
manipulation was started using an overnight culture of a frozen stock. When 
required ampicillin or chloramphenicol were added to final concentration of 
100g/ml and 30g/ml, respectively. 
 
 
5.2_Construction of plasmids and knockouts 
DNA manipulations were carried out routinely using standard laboratory methods 
(Sambrook, J. et al., 1989). The ΔompA mutant was produced by replacing ompA 
coding sequence with a chloramphenicol resistance cassette. Briefly the 
upstream and downstream regions of the ompA gene were amplified from BL21 
(DE3) genomic DNA with the specific primer pairs ompA-1/ ompA-2 and ompA-
3/ompA 4 (Table 2). In parallel, the Cm cassette was amplified from pKD3 
plasmid (Datsenko K.A. et al., 2000) using the primers CMR-for/CMR-rev. Finally 
the three amplified fragments were fused together by mixing 100 ng of each in a 
PCR containing the 1/4 primers. The linear fragment obtained, in which the 
antibiotic resistance gene was flanked by the upstream and downstream regions, 
was used to transform the recombination-prone BL21(DE3) E. coli strain (made 
electro-competent by three washing steps in cold water), and mutants were 
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selected by plating transformed bacteria on Luria-Bertani (LB) plates containing 
30g/ml Cm. Recombination-prone BL21 (DE3) cells were produced by using the 
highly proficient homologous recombination system (red operon) (Murphy K.C. 
1998). Briefly, electro-competent bacterial cells were transformed with 5g of 
plasmid pAJD434 by electroporation (5.9 ms at 2.5 kV). Bacteria were then grown 
for 1 h at 37 °C in 1 ml of SOC broth and then plated on LB plates containing 
trimethoprim (100g/ml). Expression of the red genes carried by pAJD434 was 
induced by adding 0.2% L-arabinose to the medium. The gene deletion of the 
ompA gene was confirmed by PCR genomic DNA amplification using primers 
pairs ompA-1/CMR-rev and CMR-for/ompA-4.  
Plasmids pET21_fHbp wild type, pET21_NHBA, pET21_fHbp-∆gly, pET21_ 
fHbp-ALA, pET21_ fHbp A, pET21_ fHbp A-B, pET21_ fHbp C, pET21_ fHbp 
wt-GBS59 D3,  pET21_ fHbp A-GBS59 D3, pET21_ fHbp wt-fhuD2, pET21_ 
fHbp A-spa_DEABC were generated as follows. Briefly, fHbp and nhba wild type 
genes were amplified by PCR from Neisseria meningitidis serogroup B strain 
MC58 genome using primers fHbp-ss-F/fHbp R and NHBA ss F/NHBA rev (Table 
2) respectively. Primers fHbp-ss-F and NHBA ss F were design to amplify the 
genes with their own leader sequence and lipobox for secretion and anchoring to 
the membrane. The polymerase incomplete primer extension (PIPE) cloning 
method (Klock H. et al., 2009) was used to insert the PCR products into plasmid 
pET21b which was amplified using primers pet-rev/nohisflag (Table 2). In so 
doing plasmid pET21_fHbp full length and pET21_NHBA were generated. To 
generate pET21_fHbp-∆gly and pET21_fHbp-ALA, site-directed mutagenesis was 
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performed on pET21_fHbp wild type plasmid using primers fHbp ∆gly F/fHbp ∆gly 
R and fHbp ALA F/fHbp ALA R (Table 2), in order to exclude the glycine stretch 
located downstream of the lipobox or to substitute this region with an alanine 
stretch, respectively. pET21_fHbp domain A, pET21_fHbp domain A-B and 
pET21_ fHbp domain C plasmids were generated amplifying pET21_fHbp full 
lenght  plasmid using  primers pairs: nohis flag/fHbp A rev, nohisflag/fHbp B rev, 
fHbp C for/fHbp lipo rev in order to exclude the domains B+C, the domain C and 
the domains A+B respectively. To generate pET21_ fHbp fl-GBS59 D3,  pET21 
fHbp A-GBS59 D3 plasmids,  which contain Streptococcus agalactiae GBS59 
domain 3 fused to fHbp full length or domain A respectively, GBS59 domain 3 
was amplified by PCR from S. agalactiae strain 515 genome using GBS dom 
C/GBS dom rev STOP and GBS dom-A/GBS dom rev STOP primers respectively 
and cloned into pET21_fHbp full lenght and pET21_fHbp domain A plasmids 
respectively using PIPE method. To generate pET21_ fHbp fl-fhuD2, pET21_ 
fHbp A-spa_DEABC plasmids which contain Staphylococcus aureus fhuD2 gene 
fused to fHbp full length and spa_DEABC gene fused to fHbp domain A 
respectively, fhuD2 and spa_DEABC  genes were amplified from pET21-fhuD2 
and pET21-spaDEABC plasmids  containing fhu_D2 and spa_DEABC genes, 
using primers fhu_D2 dom C for/fhu_D2 rev and spa_DEABC dom A 
for/spa_DEABC rev respectively and cloned into pET21_fHbp full lenght and 
pET21_fHbp domain A plasmids respectively using PIPE method. 
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5.3_ Expression of the heterologous proteins in BL21(DE3)ompA E. coli 
strains and OMVs preparation  
Plasmid containing the genes of interest and pET21b empty vector as negative 
control were transformed into BL21(DE3) ompA strain for protein expression. 
Recombinant clones were grown in 200 ml LB medium (starting OD600=0.05) and, 
when the cultures had reached an OD600 value of 0.5, recombinant protein 
expression was induced by addition of 1 mM IPTG After 2 hours, OMVs were 
collected from culture supernatants by filtration through a 0.22 mm pore size filter 
(Millipore) and by high-speed centrifugation (200,000 x g for 2 hours). Pellets 
containing OMVs were finally re-suspended in PBS. Total bacterial lysates were 
prepared by suspending bacterial cells from 1 ml cultures (centrifuged at 13,000 
X g for 5 minutes) and re-suspended in sodium dodecyl sulphate-polyacrylamide 
gel electrophoresis (SDS-PAGE) loading buffer, heated at 100°C for 5 minutes 
and loaded onto a 4-12% or 10% polyacrylamide gel (Invitrogen). Polyacrylamide 
gels were run in MES or MOPS buffer (Invitrogen) and stained with Coomassie 
Blue. 
 
 
5.4_Western blot analysis 
Total lysates were prepared from bacteria grown in LB broth. Liquid cultures were 
pelleted in a bench-top centrifuge and suspended in SDS-PAGE loading buffer in 
an appropriate volume to normalize cell density to a final OD600 of 10. About 10 
ml of each sample was then separated on a 4-12% SDS-PAGE (Invitrogen). For 
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quantification of fHbp heterologous protein expression 20 μg recombinant OMVs 
were loaded onto 4-12 % SDS-polyacrylamide gels along with increasing 
concentration of the corresponding purified recombinant protein used as 
standard. Empty OMVs were also loaded as a negative control. The 
polyacrylamide gels were then transferred onto nitrocellulose filter by standard 
methods. The filters were blocked overnight at 4°C by agitation in blocking 
solution (10% skimmed milk and 0.05% Tween in PBS), followed by incubation 
for 90 minutes at 37°C  with a 1:1000 dilution of the required immune sera in 3% 
skimmed milk and 0.05% Tween in PBS. After three washing steps in PBS-
Tween, the filters were incubated in a 1:2000 dilution of peroxidase-conjugated 
anti-rabbit immunoglobulin (Dako) in 3% skimmed milk and 0.05% Tween in PBS 
for an hour, and after three washing steps, the resulting signal was detected by 
using the SuperSignal West Pico chemiluminescent substrate (Pierce).   
 
          
         5.5_Proteinase K protection assay 
To investigate heterologous proteins localization in the OMVs 100 μg/ml 
proteinase K (Fermentas) was added to 30 μg intact and solubilized (in 1% SDS) 
OMVs expressing the heterologous proteins, and the mixture was then incubated 
at 37°C for 10 minutes. After proteinase K deactivation with 10mM 
phenylmethylsulfonyl fluoride (PMSF; Sigma Aldrich) samples were loaded on a 
4-12% or 10% polyacrylamide gel and Western blot analysis was performed with 
the required antibody to detect the presence of the heterologous proteins.   
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5.6_ Fluorescence-Activated Cell Sorting (FACS) analysis  
15 ml of Luria-Bertani medium was inoculated at OD600= 0.05 starting from an 
overnight culture of each transformant. Cultures were then grown until the OD600= 
0.5 (2.5 X108 CFU/mL) and expression of the recombinant proteins was induced 
by addition of 1mM IPTG and further incubation for 2 hours. BL21 E. coli strain 
transformed with pET21b empty vector was used as negative control. 1 ml of 
bacterial cells was harvested by centrifugation at 10,000 X g for 5 minutes at 4°C 
and re-suspendedin PBS + 1% BSA dilution buffer in order to obtain 2x107  
CFU/ml cells. 50 µl were then dispensed in a 96 well plate with round bottom.  
Primary antibodies against heterologous proteins were diluted at three different 
concentrations (1:50, 1:100, 1:200) and 5 µl of each dilution were added to the 
wells containing he bacteria suspension and incubated 1 h on ice. Each well was 
then washed with 100 µl PBS + 1% BSA buffer. 20 µl of commercial FITC labeled 
anti-rabbit secondary antibody diluted 1:200 in dilution buffer were added in each 
wells and incubated 1 h in ice.  Each well was then washed with 100 µl PBS + 1% 
BSA buffer and the plate was centrifuged at 4000 X g for 5 min. Samples were 
then re-suspended in formalin solution 4% , incubated 20 min a 4°C and then 
centrifuged at 4000 X g for 5 min. Samples were re-suspended in 130 µl of PBS 
and data were acquired by using BD FACS Canto II cell analyzer. 
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Table 2 - Oligonucleotide primers used in this study 
 
 
 
 
NAME SEQUENCE (5’-3’) REFERENCE 
 
nohisflag 
 
TAACATCACCATCACCATCACGATTACAAAGA 
 
pet-rev CATATGTATATCTCCTTCTTAAAGTTAAAC  
ompA-1 GATCGGTTGGTTGGCAGAT 
Fantappiè et al, 
2014 
ompA-2 CACCAGGATTTATTTATTCTGCGTTTTTGCGCCTCGTTATCAT 
Fantappiè et al, 
2014 
ompA-3 TACTGCGATGAGTGGCAGGCGCAGGCTTAAGTTCTCGTC 
Fantappiè et al, 
2014 
ompA-4 AAAATCTTGAAAGCGGTTGG 
Fantappiè et al, 
2014 
CMR-for CGCAGAATAAATAAATCCTGGTG 
Fantappiè et al, 
2014 
CMR-rev CCTGCCACTCATCGCAGTA 
Fantappiè et al, 
2014 
fHbp ∆gly R GGCGACGCTGCTGCAGGCGGTCAG This study 
fHbp ALA F GCGGCCGCGGCCGTCGCCGCCGACATCGGTG This study 
fHbp ALA R GGCCGCGGCCGCGCTGCTGCAGGCGGTCAG This study 
fHbp lipo rev ACCACCCCCTCCGCTGCTGC This study 
fHbp C for GCGGAGGGGGTGGTGGAAAACTGACCTACACCA This study 
fHbp rev GBS TTGCTTGGCGGCAAGGC This study 
fHbp A rev GBS TTGTTTGTATACTTGGAACTCTCCACTCTC This study 
GBS dom C  CTTGCCGCCAAGCAAGCAACAACCCAACAATTGAA This study 
GBS dom A  CCAAGTATACAAACAAGCAACAACCCAACAATTGAA This study 
GBS dom rev STOP GTGATGGTGATGTTATTAAGCTTTTTCTGCATCTGTTGC This study 
fHbp A rev GTGATGGTGATGTTACACCTCTCAAGGTTCATATGTTTGTT This study 
fHbp B rev GTGATGGTGATGTTATCCGCCGGCATCGTCTG This study 
nhba ss F GGAGATATACATATGTTTAAACGCAGCGTAATC This study 
nhba rev GTGATGGTGATGTTATCAATCCTGCTCTTTTTTG This study 
Fhu_D2 dom C for CTTGCCGCCAAGCAAGGGAACCAAGGTGAAAAAAATAACAAAG This study 
Fhu_D2 rev GTGATGGTGATGTTATTATTTTGCAGCTTTAATTAATTTTTCTTTTA
AATCTTTAC 
This study 
Spa DEABC dom A for CCAAGTATACAAACAAGCACAGCATGATGAAGCCAAAAAA This study 
Spa DEABC rev GTGATGGTGATGTTATTATTTAGGTGCCTGTGCGTCGTT This study 
63 
 
 
 
 
 
Table 3 – Strains and plasmids used in this study 
 
 
BACTERIAL STRAINS DESCRIPTION REFERENCE 
E. coli   
BL21-(DE3)   
∆ompA BL21-(DE3) with ompA deleted Fantappiè et 
al, 2014 
HK-100  Klock et al, 
2009 
N.meningitidis   
MC58 Wild-type Pizza et al., 
2000 
S. agalactiae   
515 Wild-type Maione et al., 
2005 
PLASMIDS DESCRIPTION REFERENCE 
pET21 Ampr, cloning vector Novagen 
pET21_fHbp full length  pET21 carrying the full length  fHbp gene from  
N. meningtidis MC58 strain  
This study 
pET21_NHBA pET21 carrying the full length  nhba gene from  
N. meningtidis MC58 strain  
This study 
pET21_fhuD2 pET21_ carrying fhuD2 gene  Mishra et al., 
2012 
pET21_spaDEABC pET21_ carrying spa_DEABC  Kim et al., 
2010 
pET21_fHbp A pET21_carrying fHbp domain A This study 
pET21_fHbp A-B pET21_ carrying fHbp domain A and B This study 
pET21_fHbp C pET21_ carrying fHbp domain C This study 
pET21_fHbp -GBSD3 pET21_fHbp full length with GBS59 domain 3 
fused at the C-terminus 
This study 
pET21_fHbp A-GBSD3 pET21_fHbp A with  GBS59 domain 3 fused at 
the C-terminus of the fHbp domain A 
This study 
pET21_fHbp –fhuD2 pET21_fHbp full length with fhuD2 fused at the 
C-terminus 
This study 
pET21_fHbp  A-spa_DEABC pET21_fHbp A with spa_DEABC fused at the 
C-terminus  of the fHbp domain A 
This study 
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Background: Outer membrane vesicles (OMVs) from Gram-negative bacteria are gaining increasing attention
as vaccine platform for their built-in adjuvanticity and for their potential use as carriers of heterologous
antigens. These 2 properties offer the opportunity to make highly effective, easy to produce multi-valent
vaccines. OMVs can be loaded with foreign antigens by targeting protein expression either to the outer
membrane or to the periplasm of the OMV-producing strain. Periplasmic expression is simple and relatively
efficient but leads to the accumulation of recombinant antigens in the lumen of OMVs and the ability of
OMVs carrying internalized antigens to induce antigen-specific antibody responses has been only marginally
investigated and is considered to be sub-optimal.
Methods: We have systematically analyzed in qualitative and quantitative terms antibody responses induced
by OMVs carrying different heterologous antigens in their lumen. Group A Streptococcus (GAS) Slo,
SpyCEP, Spy0269 and Group B Streptococcus (GBS) SAM_1372 were fused to the OmpA leader sequence
for secretion and expressed in Escherichia coli. OMVs from the recombinant strains were purified and tested
for immunogenicity and protective activity.
Results: All proteins were incorporated into the OMVs lumen in their native conformation. Upon mice
immunization, OMVs induced high functional antibody titers against the recombinant proteins.
Furthermore, immunization with Slo-OMVs and SpyCEP-OMVs protected mice against GAS lethal
challenge.
Conclusions: The efficiency of antigen delivery to the vesicular lumen via periplasmic expression, and the
surprisingly high immunogenicity and protective activity of OMVs carrying internalized recombinant
antigens further strengthens the potential of OMVs as vaccine platform.
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O
uter membrane vesicles (OMVs) are closed spher-
oid particles of heterogeneous size (10300 nm
in diameter) released by all Gram-negative bac-
teria and generated through the ‘‘budding out’’ of the
bacterial outer membrane. The production of OMVs
was originally described as an essential step for rapid
adaptation to environmental changes, but a multitude
of other functions have now been attributed to OMVs,
including delivery of toxins and virulence factors to
host cells, inter-species and intra-species cell-to-cell
cross-talk, biofilm formation, genetic transformation
and defence against innate and adaptive host immune
responses (13).
OMVs purified from several pathogens, including
Neisseria, Salmonella, Pseudomonas, Vibrio cholerae,
Burkholderia, and Escherichia coli, induce potent protec-
tive immune responses against the pathogens they derive
from, and highly efficacious anti-Neisseria OMV-based
vaccines are already available for human use (48).
Such remarkable protection is attributed to 3 key features
of OMVs. First, they carry surface-associated antigens,
usually including protective antigens. Second, they are

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readily phagocytosed by professional antigen-presenting
cells, allowing efficient presentation of OMV-derived
peptides. This results in efficient elicitation of antibodies
and extracellular antigen mediated CD4 T cell response
against OMV proteins. For instance, mice immunized
withSalmonellaOMVs develop robustSalmonella-specific
B- and T-cell responses, and OMVs also stimulate IFN-g
production by a large proportion of CD4 T cells in
mice previously infected with Salmonella, indicating that
OMVs are an abundant source of antigens recognized by
Salmonella-specific CD4 T cells (4). Third, OMVs carry
many pathogen-associated-molecular patterns (PAMPs)
which, by binding to pathogen recognition receptors
(PRRs), play a key role in stimulating innate immunity
and promoting adaptive immune responses (911). An
additional key feature of OMVs is the possibility to
manipulate their protein content by genetic engineer-
ing. Kesty and Kuehn (12) demonstrated that Yersinia
enterocolitica outer membrane protein Ail assembled on
OMVs’ surfaces when expressed in E. coli, and that the
GFP fluorescence protein fused to the ‘‘twin-arginine
transport’’ (Tat) signal sequence was incorporated in the
OMV lumen. Furthermore, several heterologous antigens
have been successfully exported to the surface of OMVs
when fused to the b-barrel forming auto transporter AIDA
and to the haemolysin ClyA, 2 proteins that naturally
compartmentalize in E. coli OMVs (1315).
For a full blown development of OMVs as vaccine
platform, a number of issues are yet to be addressed.
Among them there are 2 relevant questions. First, although
strategies to load OMVs with recombinant antigens
have been described, their general applicability remains
to be demonstrated. Second, recombinant antigens can
theoretically be engineered (a) to reach the lumen of
OMVs, either as soluble proteins or associated to the inner
leaflet of the membrane and (b) to be associated to
the membrane facing the external milieu. However, how
protein compartmentalization in OMVs affects antibody
responses deserves further investigation.
In this work, we addressed the question whether
compartmentalization of recombinant antigens in the
lumen of E. coli-derived OMVs represents a broadly
applicable approach to induce protective antibody re-
sponses. To this aim, we selected a group of heterologous
antigens and we show that all of them can be incorporated
in the lumen of E. coli-derived OMVs in a functional
conformation. Furthermore, we show that mouse immu-
nization with engineered OMVs induces functional
antibodies and protective immune responses. Altogether
our data strengthen the potential of OMVs as vaccine
platform in that they demonstrate that complex cloning
strategies to deliver recombinant antigens to the OMV
surface are not strictly necessary to promote effective
immunological responses.
Materials and methods
Bacterial strains and culture conditions
HK-100 and BL21(DE3) E. coli strains were routinely
grown in Luria-Bertani (LB) broth at 378C and used for
cloning and expression experiments, respectively. When
required, Ampicillin or Chloramphenicol were added
to a final concentration of 100 mg/ml and 30 mg/ml,
respectively.
Construction of plasmids and knockout mutants
DNA manipulations were carried out using standard
laboratory methods (16).
BL21(DE3) DompA mutant was produced by replac-
ing the ompA coding sequence with a Chloramphenicol
(Cm) resistance cassette. Briefly, the upstream and down-
stream regions of the ompA gene were amplified from
BL21 (DE3) genomic DNA with the specific primer pairs
ompA-1/ompA-2 and ompA-3/ompA-4 (Table I). In
parallel, the Cm cassette was amplified from pKD3
plasmid (17) using the primers CMR-for/CMR-rev.
Finally, the 3 amplified fragments were fused together
by mixing 100 ng of each in a PCR reaction containing
primers ompA-1 and ompA-4. The obtained linear
fragment, in which the antibiotic resistance gene was
flanked by the upstream and downstream regions of ompA
gene, was used to transform BL21(DE3) E. coli (made
electro-competent by 3 washing steps in cold water).
DompA mutant colonies were selected by plating trans-
formed bacteria on LB plates containing 30mg/ml Cm.
Recombination-prone BL21 (DE3) cells were obtained by
the highly proficient homologous recombination system
(red operon) (18). Briefly, electro-competent bacterial cells
were transformed with 5 mg of plasmid pAJD434 by
electroporation (5.9 ms at 2.5 kV). Bacteria were then
grown for 1 hour at 378C in 1 ml SOC broth and then
plated on LB plates containing Trimethoprim (100 mg/ml).
Expression of the red genes carried by pAJD434 was
induced by adding 0.2% L-arabinose to the medium.
Deletion of the ompA gene was confirmed by genomic
DNA amplification using the primer pairs ompA-1/CMR-
rev and CMR-for/ompA-4 (Table I).
Plasmids pET21_bla, pET21_slo, pET21_slo-dm,
pET21_spycep, pET21_spy0269 and pET21_sam1372
were generated as follows. slo, spycep and spy_0269
genes were amplified by PCR from M1 3348 Group A
Streptococcus (GAS) strain (19) using primers GAS25-F/
GAS25-R, spyCEP-F3/spyCEP-R3 and Spy0269-F/
Spy0269-R (Table I), respectively. The gene encoding
inactive Slo was cloned from plasmid pET24-slo-dm (20)
using GAS25-F/GAS25-R primers. The beta-lactamase
gene was amplified using pET-21b plasmid DNA as
template and primers bla-omp-F and bla-omp-R. Finally,
amplification of Streptococcus agalactiae sam_1372 gene
from the CJB111 genome was conducted using primers
Laura Fantappie` et al.
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SAM_1372-F and SAM_1372-R. Primers were designed
to amplify the genes without their natural leader
sequence for secretion and, in the case of SpyCEP and
SAM_1372, the C-terminal cell wallanchoring domains
(aa 16141647 and aa 620674, respectively) were also
omitted. The polymerase incomplete primer extension
(PIPE) cloning method (21) was used to insert all PCR
products into plasmid pETOmpA, a pET21 derivative
carrying the sequence encoding the leader peptide
for secretion of E. coli OmpA, which was amplified
using primers omprev/nohisflag (Table I). In so doing,
all recombinant proteins were expressed fused to the
OmpA leader sequence. Cytoplasmic expression of the
proteins was accomplished by cloning the amplified genes
into a pETOmpA derivative plasmid in which the ompA
leader sequence was removed using the primers pet-rev/
nohisflag (Table I) for PIPE amplification. The plasmids
encoding the genes without signal peptide were named
pET21_spycep-noLS, pET21_spy0269-noLS, pET21_slo-
noLS and pET21_sam1372-noLS.
Expression of the heterologous proteins in
BL21(DE3)DompA E. coli strain and OMVs
preparation
pET plasmid derivatives containing the genes of interest
were transformed into BL21(DE3) DompA strain. Re-
combinant clones were grown in 200 ml LB medium
(starting OD6000.05) and, when the cultures had
reached an OD600 value of 0.5, recombinant protein
expression was induced by addition of 1 mM IPTG.
After 2 hours, OMVs were collected from culture super-
natants by filtration through a 0.22 mm pore size filter
(Millipore) and by high-speed centrifugation (200,000g
for 2 hours). Pellets containing OMVs were finally
suspended in PBS. Total bacterial lysates were prepared
by suspending bacterial cells from 1 ml cultures (cen-
trifuged at 13,000g for 5 minutes) in sodium dodecyl
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
loading buffer, heated at 1008C for 5 minutes and loaded
onto a 412% polyacrylamide gel (Invitrogen). Polyacry-
lamide gels were run in MES buffer (Invitrogen) and
stained with Coomassie Blue.
Western blot analysis
Total lysates were prepared from bacteria grown in
LB broth. Liquid cultures were pelleted in a bench-top
centrifuge and suspended in SDS-PAGE loading buffer
in an appropriate volume to normalize cell density to
a final OD600 of 10. About 10 ml of each sample was
then separated on a 412% SDS-PAGE (Invitrogen). For
quantification of heterologous protein expression, 30 mg
of OMVs were loaded onto 412% SDS-polyacrylamide
gels along with increasing concentrations of the corre-
sponding purified recombinant protein used as standard.
Table I. Oligonucleotide primers used in this study
Name Sequence
slo-F ACCGTAGCGCAGGCCAACAAACAAAACACTGCTAGTACAG
slo-R GTGATGGTGATGTTACTACTTATAAGTAATCGAACCATATG
SpyCEP-F3 ACCGTAGCGCAGGCCGCAGCAGATGAGCTAAGCACAATGAGCGAACC
SpyCEP-R3 GTGATGGTGATGTTATTAGGCTTTTGCTGTTGCTGAGGTCGTTGACTTGGTTGG
Bla-omp-F ACCGTAGCGCAGGCCCGGTAAGATCCTTGAGATTTTTCG
Bla-omp-R GTGATGGTGATGTTATTACCAATGCTTAATCAGTGAGGC
omprev GGCCTGCGCTACGGTAGCGAAA
nohisflag TAACATCACCATCACCATCACGATTACAAAGA
ompA-1 GATCGGTTGGTTGGCAGAT
ompA-2 CACCAGGATTTATTTATTCTGCGTTTTTGCGCCTCGTTATCAT
ompA-3 TACTGCGATGAGTGGCAGGCGCAGGCTTAAGTTCTCGTC
ompA-4 AAAATCTTGAAAGCGGTTGG
CMR-for CGCAGAATAAATAAATCCTGGTG
CMR-rev CCTGCCACTCATCGCAGTA
Spy0269-F ACCGTAGCGCAGGCCGATGATAGAGCCTCAGGAGAAACG
Spy0269-R GTGATGGTGATGTTATCACTTAGATTCCTTACGGAACC
SAM_1372-F ACCGTAGCGCAGGCCGACGACGCAACAACTGATAC
SAM_1372-R GTGATGGTGATGTTAGGTTACTTTTTTGTTTTGAACTTGTTGGG
Pet-rev CATATGTATATCTCCTTCTTAAAGTTAAAC
Slo-F-no GGAGATATACATATGAACAAACAAAACACTGCTAGTACAG
Spycep-F-no GGAGATATACATATGGCAGCAGATGAGCTAAGCACAATGAGCGAACC
Spy_0269-F-no GGAGATATACATATGGATGATAGAGCCTCAGGAGAAACG
SAM_1372-F-no GGAGATATACATATGGACGACGCAACAACTGATAC
OMVs carrying heterologous antigens in their lumen
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The gels were then transferred onto nitrocellulose filters
by standard methods (16). The filters were blocked
overnight at 48C by agitation in blocking solution (10%
skimmed milk and 0.05% Tween in PBS), followed by
incubation for 90 minutes at 378C with a 1:1,000 dilution
of the required immune sera in 3% skimmed milk and
0.05% Tween in PBS. Anti-Bla and anti-Mbp antibodies
were obtained from Abcam, while antibodies against
Slo, SpyCEP, Spy_0269 and SAM_1372 were produced
by immunizing mice with 3 doses of recombinant proteins
(10 mg/dose) formulated in Alum. After 3 washing steps
in PBS-Tween, the filters were incubated in a 1:2,000
dilution of peroxidase-conjugated anti-mouse immuno-
globulin (Dako) in 3% skimmed milk and 0.05% Tween
in PBS for 1 hour, and after 3 washing steps, the resulting
signal was detected using the Super Signal West Pico
chemo-luminescent substrate (Pierce).
Laser scattering analysis
The size distribution profile of OMVs was determined
by dynamic light scattering based on laser diffrac-
tion method employing Malvern Zetasizer (Version 6.0,
Malvern, UK). The OMV diameter was determined after
dilution in PBS (1/100) and by measuring the back
scattering intensity (1758) at 258C. Three measurements
(15 experimental runs per measurement) were averaged to
determine the vesicles size.
Lipopolysaccharide quantification
Lipopolysaccharide (LPS) content was determined using
the limulus amoebocyte lysate (LAL) assay (Thermo
Scientific). Briefly, OMVs were diluted in pyrogen-free
water and 50 ml were combined with 50 ml LAL reagent
and incubated at 378C for 10 minutes prior to addition of
a chromogenic substrate. Absorbance was then measured
at 405 nm. LPS concentration was estimated from a
standard curve prepared with E. coli endotoxin standard.
Proteinase K protection assay
To confirm that heterologous proteins were expressed
in the lumen of OMVs, proteinase K (Fermentas) was
added to 15 mg of intact or solubilized (in 1% SDS)
OMVs at a final concentration of 100 mg/ml, and the
mixture was then incubated at 378C for 10 minutes. After
proteinase K deactivation with 10 mM phenylmethylsul-
fonyl fluoride (PMSF; Sigma Aldrich), samples were
loaded onto a 412% polyacrylamide gel and Western
blot analysis was performed as described above.
Functional assays
To measure SpyCEP hydrolytic activity on IL-8, OMVs
expressing SpyCEP were permeabilized with 1% Triton
X-100 at room temperature for 20 minutes and subse-
quently incubated at different concentrations with human
IL-8 (50 mg/ml; Peprotech) at 378C for 2 hours. Hydro-
lysis of IL-8 was followed by SDS-PAGE (18%).
Slo haemolytic activity was tested by incubating
OMVs expressing the wild type form of the toxin with
sheep blood erythrocytes as follows. About 50 ml of serial
dilutions (in PBS0.5% BSA) of OMVs were dispensed
into 96-well plates with U-shaped bottom. Erythrocytes
were collected by centrifugation (3,000g for 5 minutes)
from 1 ml of sheep blood, washed 3 times in PBS and
finally suspended in 5 ml of PBS. About 50 ml of this
suspension were added to each well and incubated
at 378C for 30 minutes. As positive control, erythrocytes
were added to wells containing 50 ml of water (under
these ipotonic conditions erythrocytes completely lyse)
while, as negative control, blood cells were incubated with
permeabilized OMVs prepared from BL21(DE3) DompA
strain carrying pETOmpA vector plasmid (from now
on defined as ‘‘empty OMVs’’ to indicate that they do
not carry any heterologous antigen). Plates were then
centrifuged for 5 minutes at 1,000g, the supernatants
were transferred to 96-well flat-bottomed plates and
absorbance was measured at 540 nm.
OMVs expressing b-lactamase (Bla) were incubated
with the chromogenic substrate nitrocefin and the Bla
activity was measured as follows. OMVs were permeabi-
lized in 1% Triton X-100 at room temperature for
20 minutes and different aliquots were incubated
with nitrocefin (0.5 mg/ml; Oxoid, Thermo Scientific,
Cambridge, United Kingdom) for 30 minutes at 378C
in the dark. Hydrolysis was determined at OD485 and
Bla concentration was calculated using a standard curve
obtained with purified Bla (VWR).
Mice immunization
Five-week old CD1 female mice were immunized intraper-
itoneally (i.p.) on days 0, 21 and 35 with 25 mg of OMVs
and, unless otherwise specified, with 20 mg or 0.5 mg
of recombinant proteins formulated in 2 mg/ml Alum
hydroxide as adjuvant. Mouse sera were collected before
the first immunization (pre-immune sera) and 2 weeks
after each immunization. In challenge studies, 3 weeks
after the third immunization mice were given 23106
colony forming unit (CFU) of M1 3348 GAS strain, via i.p.
Mice survival was monitored daily for a 7-day period.
All procedures were approved by the National Health
Institution and Novartis Vaccines Animal Care and
Ethical Committee and for humanitarian reasons animals
were sacrificed at symptoms of sickness as recommended
by 3Rs rules (‘‘Refinement, Reduction, Replacement’’
policy towards the use of animals for scientific procedures
 99/167/EC, Council Decision of 25/1/99).
ELISA
Ninety six-well Maxisorp plates (Nunc, Thermo Fisher
Scientific) were coated with 3 mg/ml of purified recombi-
nant antigens in PBS. Plates were incubated for 2 hours
at room temperature, then washed 3 times with TPBS
(0.05% Tween 20 in PBS, pH 7.4) and blocked with
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250 ml/well of 2% BSA (SigmaAldrich) for 1 hour at
room temperature. Each incubation step was followed
by triple TPBS wash. Serum samples were initially diluted
1:100,000 in 2% BSA in TPBS, transferred to coated-
blocked plates (200 ml) and serially 2-fold diluted
followed by 2 hours incubation at 378C. Then 100
ml/well of 1:2,000 diluted alkaline phosphatase-conju-
gated goat anti-mouse IgG (Sigma-Aldrich) or IgM, or
IgG1, or IgG2A (Southern Biotechnologies) were added
and left for 2 hours at 308C. Bound alkaline phosphatase
was visualized by adding 100 ml/well of 3 mg/lL para-
nitrophenyl-phosphate disodium hexahydrate (Sigma
Aldrich) in 1 M diethanolamine buffer (pH 9.8). After
10 minutes at room temperature, plates were analyzed
at 405 nm in a microplate spectrophotometer and anti-
body titers (expressed as EU/ml) were calculated using a
reference calibration curve.
Opsonophagocytosis assay
The opsonophagocytosis assay (OPA) was performed
using Group B Streptococcus (GBS) strain CJB111 as
target bacteria and HL-60 cell line (ATCC; CCL-240)
differentiated into granulocyte-like cells by adding 100
mM N, N Dimethylformamide (Sigma) to the growth
medium for 4 days. Mid-exponential bacteria were incu-
bated at 378C for 1 hour in the presence of phagocytic
cells, 10% baby rabbit complement (Cederlane) and heat-
inactivated mouse antisera. Negative controls consisted of
reactions either with pre-immune sera, or without HL-60,
or with heat-inactivated complement. For each serum
sample, 6 serial dilutions (1:2) were tested. The reaction
plates were incubated for 1 hour at 378C and 300 rpm
(Eppendorf Thermomixer) and the number of CFUs at
the time zero (T0) and after 1 hour (T60) were com-
pared. Bacterial killing was calculated as follows: killing
(%)[(mean CFU at T0 - mean CFU at T60)/mean CFU
at T0]*100. OPKA titers were expressed as the reciprocal
serum dilution leading to 50% killing of bacteria.
Results
Heterologous antigens expressed in the E. coli
periplasm are incorporated into OMVs
To test whether the delivery of antigens into the OMV
lumen by periplasmic expression is broadly applicable,
we selected 3 proteins from GAS (the cell wallanchored
protein SpyCEP (22), the secreted toxin Streptolysin O
(23) and the putative surface exclusion protein Spy0269
(19)), 1 protein from GBS (the cell-wall anchored pilus
subunit SAM_1372 (24)) and 1 from E. coli (the peri-
plasmic TEM1 b-lactamase, a protein shown to be
incorporated into the OMVs of Pseudomonas aeruginosa
and Moraxella catarrhalis (25,26)) (Table II).
Antigen selection was based on 3 criteria: their
belonging to different cellular compartments, their hav-
ing a measurable functional activity and their capacity to
induce antibody-mediated protective immune responses
in animal models. The first criterion addresses whether
specific categories of proteins are more or less prone
to reach the periplasm and be delivered to the OMVs.
The second criterion was selected to exploit functional
activity as a surrogate for antigen folding. Finally, the
third criterion allows evaluating the quantity and quality
of antibody responses elicited by the recombinant anti-
gens once incorporated inside the OMVs.
All genes were cloned into the pETOmpA plasmid,
a derivative of pET21b carrying the coding sequence of
the E. coli OmpA signal peptide downstream from the T7
inducible promoter, thus allowing N-terminal fusion of
the E. coli periplasmic secretion sequence to the protein
of interest. Because of the presence of the OmpA leader
sequence, all proteins (except TEM1 beta-lactamase)
were cloned without their natural secretory signal.
Furthermore, the C-terminal cell-wall anchoring domains
of SpyCEP and SAM_1372 (amino acids 1,6141,647
and amino acids 620674, respectively) were also elimi-
nated. In summary, 5 plasmids were generated, pET21_
bla, pET-21_slo, pET21_spycep, pET21_spy0269 and
pET21_sam1372, which were used to transform the
OMV overproducer strain E. coli BL21(DE3) DompA.
The derived strains were grown to mid-log phase and
antigen expression was induced for 2 hours by addition of
1 mM IPTG. Figure 1a shows SDS-PAGE analysis of
total lysates of cultures obtained with or without IPTG
induction. As shown in the figure, all antigens appeared
to be expressed after induction.
We next asked the question whether the proteins
reached the OMV compartment. To this aim, after
2 hours’ induction with IPTG, OMVs were purified from
bacterial culture supernatants as described in Materials
Table II. Antigens used for expression in OMVs
Antigen Pathogen Functional assay Protective immune responses
SpyCEP S. pyogenes IL-8 cleavage Neutralizing Ab and mouse challenge
Streptolysin O S. pyogenes Haemolysis Neutralizing Ab and mouse challenge
Spy0269 S. pyogenes Not available Mouse challenge
SAM_1372 S. agalactiae Not available Opsonophagocytic activity
R-TEM b-lac E. coli Hydrolysis of Nitrocefin Not available
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and Methods and analyzed by SDS-PAGE. As shown
in Fig. 1b, all proteins were found in the OMVs at levels
ranging from 0.5% to approximately 10% of total OMV
proteins, as judged by Western Blot protein quantitation
analysis in which different amounts of purified recombi-
nant antigens were used as standard controls (Fig. 1d).
The proteins that showed the lowest level of expression in
OMVs were SAM_1372 and Spy0269, both representing
approximately 0.5% of total OMV proteins. Bla, Slo and
SpyCEP represented between 5 and 10% of total OMV
proteins. Antigen fusion to the OmpA leader sequence was
indispensable for protein delivery to the OMVs. In fact,
when the proteins were not fused to the OmpA leader
sequence (see Material and Methods), all antigens accu-
mulated in the cytoplasm and were not found in OMVs,
as judged by Western Blot analysis (Fig. 1c).
In order to assess the size and the homogeneity of
the purified vesicles, they were analyzed by light scatter-
ing (see Materials and Methods). As shown in Fig. 2,
vesicle size ranged from 20 to 300 nm, and the majority
of vesicles had a diameter of 80140 nm. Vesicle
dimension was not affected by the presence of different
recombinant antigens, and size distribution of vesicles
stored at 208C did not vary over a period of 1 month
(data not shown).
Although recombinant antigens should reside in the
internal space of the vesicles, the unexpected evidence
that HtrA, a Chlamydia trachomatis protein we recently
expressed in OMVs (27), was at least partially exposed
on the OMV surface, prompted us to further investigate
the location of the 5 antigens in OMVs. To this aim,
purified OMVs were treated with proteinase K either
in the presence or in the absence of 1% SDS. As shown
in Fig. 3, recombinant antigens were digested by the
protease only in the presence of detergent, indicating
that they became protease sensitive only upon disruption
of the OMV membrane.
Taken together these results demonstrate that antigen
fusion to a sec-dependent leader sequence for secretion is
sufficient to guarantee antigen targeting to the internal
Fig. 1. Expression of heterologous antigens in OMVs  (a) SDS-PAGE analysis of E. coli BL21DompA total cell extracts expressing
selected antigens. Bacteria were grown to mid-log phase and recombinant protein expression induced () or not induced () with
IPTG; 1 ml aliquots were collected by centrifugation, suspended in 100 ml of SDS-PAGE loading buffer and 25 ml aliquots were loaded
in each lane. Bands corresponding to recombinant antigens are boxed. (b) SDS-PAGE analysis of OMV from E. coli BL21DompA
expressing selected antigens. OMVs were purified by ultracentrifugation of 200 ml bacterial culture supernatants and pellets were
suspended in 200 ml of PBS. Aliquots corresponding to 30 mg of total OMV proteins were added with SDS-PAGE loading buffer and
loaded to each lane. Bands corresponding to recombinant antigens are boxed. (c) Western Blot analysis of total cell extracts and OMVs
from E. coli BL21DompA expressing the selected antigens in their cytosol. Bacteria were grown to mid-log phase and protein expression
was induced with IPTG. OMVs were purified from the culture supernatants by ultracentrifugation; antigen expression was assessed in
total cell lysates (TL) and in the purified OMV fraction using antigen-specific polyclonal antibodies. Polyclonal antibodies against the
periplasmic Maltose binding protein (Mbp) were used as a control for OMV quantitation and integrity. (d) Estimation of the amount of
heterologous proteins incorporated into OMVs. Different quantities of purified recombinant proteins and OMVs expressing the protein
of interest were analyzed by Western Blot. From the comparison of band intensities, the following percentages (mg of antigen expressed
in OMVs/mg of total proteins 100) were estimated: Bla: 5%; Slo: 5%; SpyCEP: 10%; Spy0269: 0.51%; SAM_1372: 0.5%.
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space of OMVs, suggesting that no major selection
processes take place to determine which periplasmic
protein should or should not be taken up by OMVs
during vesiculation.
Heterologous antigens expressed in the lumen of
OMVs preserve their native conformation
We next investigated whether recombinant antigens
expressed in the lumen of OMVs had a 3D structure
similar to their native conformation. This is an important
prerequisite to guarantee that, when OMVs are used in
immunization, the antigens can elicit functional antibody
responses. As surrogate of antigen folding, we measured
the functional activity of Slo, SpyCEP and R-TEM
b-lactamase. In particular, Slo haemolytic activity was
tested by incubating increasing concentrations of Slo-
OMVs with sheep blood erythrocytes. As shown in
Fig. 4a, 100% haemolysis was observed when 50 mg
of OMVs (total protein content) were added to the
reaction mixture. Considering that this amount of OMVs
corresponds to approximately 2 mg of Slo, the kinetics of
haemolysis was in line with that previously reported using
purified recombinant Slo (20). The enzymatic activity of
OMVs-containing SpyCEP was measured by incubating
human IL-8 (50 mg/ml) with Triton-permeabilized OMVs
and following the hydrolysis of IL-8 by SDS-PAGE.
As shown in Fig. 4b (lane 3), IL-8 was completely cleaved
after 30 minutes’ incubation with 4.5 mg of OMVs
(corresponding to approximately 450 ng of SpyCEP).
As in the case of Slo, the specific activity of OMV-
internalized SpyCEP appeared to be similar to recombi-
nant SpyCEP purified from the E. coli cytoplasm (28).
Finally, to determine the b-lactamase activity in OMVs,
the hydrolysis of the chromogenic substrate nitrocefin
was investigated after incubation with vesicles (Fig. 4c).
Again, estimating that b-lactamase corresponded to
approximately 5% of total OMV proteins, the specific
activity of the enzyme in OMVs was similar to the one
of purified R-TEM b-lactamase. Interestingly, assuming
that the specific activity of R-TEM in OMVs is compar-
able to the specific activity of the purified enzyme,
we estimated that 23 ng of b-lactamase were present in
1 mg of OMV, corresponding to 2.5% of total proteins.
This number is in line with our estimation of enzyme
concentration based on Western Blot analysis.
Taken together these results indicate that heterologous
antigens expressed in the lumen ofE. coliOMVs preserved
their native conformation and biological activity.
Heterologous antigens expressed in the lumen of
OMVs are immunogenic
Having demonstrated that the conformation of antigens
delivered to the lumen of OMVs is similar to their native
structure, at least as judged by functional activity, we
next investigated whether, despite the fact that they are
localized inside the vesicles, those antigens are capable of
inducing specific antibody responses. To this aim, mice
were i.p. immunized 3 times at 2-week intervals with
25 mg of OMVs and antigen-specific antibody titers were
measured collecting blood samples 2 weeks after the
last dose. For these experiments, the immunogenicity of
Slodm-OMV, SpyCEP-OMV and SAM_1372-OMVs was
investigated. Slodm is a mutated form of Slo, carrying
2 point mutations which inactivate the enzymatic activity
of the antigen without affecting its immunogenic proper-
ties (20). As shown in Fig. 5, the 3 recombinant OMVs
induced antigen-specific antibody responses which, in the
case of Slodm-OMVs and SpyCEP-OMVs, were in the
Fig. 2. Analysis of OMV dimension by light scattering  The
size of OMVs released from E. coli BL21DompA strain
expressing SAM_1372, SpyCEP, Slo, or no antigens was
determined by dynamic light scattering, measuring the back
scattering intensity (1758) at 258C. The graph represents the
average size distribution from 3 independent measurements.
Fig. 3. Analysis of antigen localization in OMVs.  Purified OMVs expressing heterologous proteins were incubated with and without
proteinase K in the presence or absence of 1% SDS. Samples were then subjected to SDS-PAGE and Western Blot analysis using
antigen-specific polyclonal antibodies. The data indicate that all recombinant antigens are localized in the lumen of OMVs.
OMVs carrying heterologous antigens in their lumen
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same range as the titers elicited by 20 mg doses of
the corresponding recombinant antigens formulated in
Alum. When the 20 mg doses of Slodm and SpyCEP
were mixed together with 25 mg of ‘‘empty OMVs,’’ an
appreciable increase (approximately 5-fold) in antibody
titers was observed highlighting the strong adjuvanticity
of the vesicles. As far as SAM_1372-OMVs are con-
cerned, they induced SAM_1372 antibody titers that
were approximately 10-fold lower than those elicited by
vaccination with Alum-formulated recombinant
SAM_1372 (10 mg/dose). This might reflect the relatively
poor expression of this antigen in OMVs, estimated to be
in the range of 0.5% of total OMV proteins (Fig. 1d).
No specific antibody titers were detected when mice
were immunized with empty OMVs or Alum alone as
controls.
One interesting property of OMVs is their built-
in adjuvanticity and their ability to skew immune res-
ponses towards a Th1/Th17 profile (4,911,29). Since
the measurement of IgG1/IgG2A ratio is routinely used
in mice as a surrogate to establish the type of immune
response induced (high and low IgG1/IgG2A ratios
indicating a TH2-type and a TH1-type of response,
respectively (30,31)), we analyzed the isotype of antigen-
specific antibodies upon immunization of mice with
recombinant OMVs carrying Slo and SpyCEP. The
isotype profiles were compared to the ones obtained
immunizing animals with Alum-formulated recombinant
proteins. As shown in Fig. 6, while purified proteins
induced antibodies predominantly belonging to IgG1
isotype, IgG2A was the predominant isotype of antigen-
specific antibodies obtained after immunization with
recombinant OMVs. As expected for immunization re-
gimes involving 3 doses, no antigen-specific IgM anti-
bodies were detectable in sera from mice immunized with
either purified antigens or recombinant OMVs.
Overall, these data seem to confirm the capacity
of OMVs to direct the immune response towards a
TH1 profile. However, to establish the precise nature of
immunity induced, a direct measurement of cytokines
and the characterization of T cell subpopulations will be
required. In particular, it will be interesting to analyze
Fig. 4. Analysis of the functional activities of protein antigens expressed in the lumen of OMVs  (a) Haemolytic activity of Slo-OMVs.
Aliquots of purified OMVs were incubated with sheep erythrocytes and absorbance at OD540 was measured from the supernatant of
each sample. Haemolytic activity is expressed as percentage of OD values over the OD values obtained incubating erythrocytes with
water (100% haemolysis). (b) Proteolytic activity of SpyCEP-OMVs. 10 mg of SpyCEP-OMVs and ‘‘empty’’ OMVs were permeabilized
with Triton X-100 and subsequently incubated with IL-8. IL-8 hydrolysis was followed by Western Blot analysis using anti-IL-8 specific
antibodies. (c) b-lactamase activity of Bla-OMVs  Bla-OMVs and ‘‘empty’’ OMVs were permeabilized with Triton X-100, and b-
lactamase activity was monitored by following the hydrolysis of nitrocefin at OD485. b-lactamase concentration in OMVs (ng of active
enzyme/mg OMVs) was estimated using a standard curve obtained with purified b-lactamase as determined by spectrophotometry.
Fig. 5. IgG titers elicited in mice immunized with Slo-OMVs
(a), SpyCEP-OMVs (b) and SAM_1372-OMVs (c). Groups of
6 CD1 female mice were immunized i.p. 3 times at 2-week
intervals with the following immunogens formulated in Alum:
25 mg OMVs expressing the recombinant antigens (Slo-OMVs,
SpyCEP-OMVs, SAM_1372-OMVs), 20 mg of purified recom-
binant antigen (Slo, SpyCEP, SAM_1372), 25 mg empty
OMVs combined with 20 mg of purified recombinant antigen
(OMVsSlo, OMVsSpyCEP), adjuvant alone (Alum). Sera
were collected 2 weeks after the third immunization and IgG
titers were analyzed by ELISA, using plates coated with the
corresponding recombinant antigen (1 mg/well). Each symbol
represents the ELISA value of an individual mouse. Horizontal
bars represent the geometric mean values within each group.
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the presence of CD4TH17 cell subset, as recently elegantly
determined by Kim and co-workers (29).
Immunization with OMVs carrying recombinant
antigens in their lumen induces antigen-specific
functional antibodies
Having demonstrated that immunization with recombi-
nant vesicles elicited antigen-specific antibodies, we
next investigated whether these antibodies displayed
functional activity. Since recombinant Slo, SpyCEP
and SAM_1372 induce antibodies which neutralize Slo
haemolytic activity, inhibit IL-8 cleavage and promote
complement-dependent opsonophagocytosis, respectively
(19,24), we analyzed whether sera from mice immunized
with recombinant OMVs had similar functions. To this
aim, recombinant SpyCEP was incubated with different
dilutions of sera from mice immunized with either 20 mg
of recombinant SpyCEP, or with 20 mg of recombinant
SpyCEP25 mg of ‘‘empty’’ OMVs or with 25 mg of
SpyCEP-OMVs, and purified IL-8 was subsequently
added to each mixture. As shown in Fig. 7a panel (i),
sera from mice receiving 3 doses of each vaccine similarly
inhibited IL-8 cleavage in a dose-dependent manner.
Interestingly, when sera from mice immunized with
2 doses of vaccines were tested, mice given SpyCEP-
OMVs had higher titers of functional antibodies
with respect to mice that received either recombinant
SpyCEP or recombinant SpyCEP‘‘empty’’ OMVs
(Fig. 7a panel (ii)). Similarly, purified recombinant Slo
was pre-incubated with different dilutions of sera from
mice immunized with 3 doses of OMV-Slo and subse-
quently goat erythrocytes were added to the mixtures.
As shown in Fig. 7b, haemolysis was effectively inhib-
ited at serum dilutions up to 1:250 and inhibition levels
were at least equal to those obtained with sera from mice
immunized with 0.5 mg of recombinant Slo, a dose close
to that estimated for 25 mg of OMVs (approx. 1 mg of
Slo). Finally, OPK titers of sera from mice immunized
with 3 doses of SAM_1372-OMVs were determined
and compared to those from animals immunized with
10 mg/dose of recombinant SAM_1372. While the anti-
body titers induced by SAM_1372-OMVs were rela-
tively low with respect to those induced by the purified
recombinant antigen (Fig. 5), engineered vesicles elicited
5-fold higher bactericidal antibody titers compared to the
recombinant antigen (Fig. 7c).
In conclusion, not only OMVs carrying heterologous
antigens in their lumen induced antigen-specific antibo-
dies but also such antibodies had potent functional
activities which could exceed, in terms of either time of
elicitation or potency of the immune response, those
obtained with the corresponding recombinant antigens
Immunization with Slo-OMVs and SpyCEP-OMVs
protects mice against S. pyogenes infection
We have previously shown that immunization with
SpyCEP and Slo protected mice from GAS lethal
challenge (19). Therefore, we tested whether, in addition
Fig. 6. Isotype analysis of antibodies elicited in mice immunized with Slo-OMVs and SpyCEP-OMVs  Sera from mice immunized i.p.
3 times with 25 mg OMVs expressing Slo or SpyCEP antigen (triangles) and with 20 mg of purified recombinant Slo or SpyCEP (squares)
were serially diluted and Ig isotypes were analyzed by ELISA using plates coated with the corresponding recombinant antigens.
Alkaline phosphatase-conjugated goat anti-mouse IgG, IgM, IgG1 and IgG2A were used as secondary antibodies. Graphs represent the
OD values obtained for each serum dilution.
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to eliciting functional antibodies, vaccination of mice
with vesicles carrying Slo and SpyCEP could induce
protective immunity. To this aim, mice were i.p. immu-
nized with 3 doses of either Slo-OMVs or SpyCEP-
OMVs (25 mg/dose) and subsequently i.p challenged with
a lethal dose of M1-3348 GAS strain. In this sepsis
model, death mainly occurs during the first 2 days,
and survival is reported after day 7. As shown in Fig. 8,
both OMVs induced robust protection against bacte-
rial challenge and protection levels were at least equal
to those observed by immunization with 20 mg/dose of
recombinant proteins.
Fig. 7. Analysis of functional antibodies induced by immunization with Slo-OMVs, SpyCEP-OMVs and SAM_1372-OMVs  (a)
Inhibition of IL-8 hydrolysis by sera from mice immunized with SpyCEP-OMVs. IL-8 hydrolysis was followed as described in Materials
and Methods in the presence of serial dilutions of sera from mice immunized with 3 (i) or 2 (ii) doses of the different immunogens.
Graphs show the percent of residual IL-8 measured after hydrolysis. Sera from each group were pooled and bars represent the geometric
mean values from 3 independent experiments. (b) Inhibition of haemolytic activity of sera from mice immunized with Slo-OMVs.
Haemolysis of sheep erythrocytes was measured in the presence of increasing dilutions of sera from mice immunized with the different
immunogens. Haemolytic activity is expressed as percentage of OD values over the OD values obtained incubating erythrocytes with
water (100% haemolysis). Sera from each group were pooled and bars represent the geometric mean values of 3 independent
experiments. (c) Opsonophagocytosis activity of sera from mice immunized with SAM_1372-OMVs. OPK was carried out as described
in Materials and Methods using the pools of sera from mice immunized as described in Fig. 5. Titers are expressed as serum dilutions
resulting in 50% bacterial killing.
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Discussion
Kesty and Kuehn (12) have been the first to demon-
strate that the protein content of bacterial OMVs can be
manipulated by targeting heterologous proteins to the
outer membrane and/or to the periplasmic space of Gram-
negative bacteria. In light of the potent adjuvant property
of OMVs, which stimulate cell-mediated and humoral
immune responses when given both systemically and
mucosally, the pivotal observation by Kesty and Kuehn
pointed towards OMVs as a potentially ideal platform
to develop highly effective, easy to produce multi-valent
vaccines.
However, for OMVs to become broadly applicable, a
number of questions remain to be addressed. Among
them, it is important to demonstrate the robustness of the
genetic engineering strategies for antigen delivery to the
OMVs and to identify the most appropriate strategy for
inducing the desired immune responses (cell-mediated
immunity and/or antibody responses).
Theoretically, the best way to elicit antigen-specific
antibody responses using engineered OMVs is to localize
recombinant antigens on the vesicle surface, thus pro-
viding the best antigen accessibility for B cell receptor
binding. However, targeting proteins to bacterial outer
membrane can be challenging and usually requires the
construction of chimera between antigen and endogenous
outer membrane proteins (1315). The success of such
fusion strategies usually inversely correlates with the size
of the passenger protein. An easier approach to deliver
recombinant antigens to OMVs would be to express them
in the bacterial periplasm. Since periplasmic proteins get
trapped in the OMV lumen during vesicle formation (2),
the addition of a sec-dependent leader sequence to the
N-termini of antigens should be sufficient to guarantee
their incorporation into OMVs, provided that no selec-
tive periplasmic protein inclusion/exclusion occurs during
vesiculation. However, luminal localization of antigens
could be a sub-optimal way to induce an antigen-specific
antibody response, unless membrane integrity is partially
lost at the site of OMVs injection with concomitant
exposure of their cargo to B cells.
In this work, we focused our attention on antigen
delivery to the OMVs with the aim of establishing in a
systematic manner (a) how efficiently heterologous pro-
tective antigens can be incorporated into the lumen of
the vesicles and (b) to what extent antigens localized in
the OMV lumen can elicit functional, antigen-specific
antibody responses.
As far as the first question is concerned, our data
demonstrate that all antigens selected in this study could
be delivered to the E. coli vesicles by hooking them to the
E. coli OmpA leader sequence for secretion. In addition,
3 heterologous antigens were previously reported to reach
the OMVs via periplasmic expression (12,32,33), and
we have recently achieved OMV delivery of 5 addi-
tional protective antigens from gram-positive pathogens
(unpublished). In light of the foregoing results, we con-
clude that most bacterial antigens eliciting antibody-
mediated protection can be successfully incorporated
into E. coli OMVs via the sec-dependent pathway of
periplasmic expression. This conclusion also implies that,
differently from that proposed for at least some outer
membrane proteins (34), vesiculation does not use a
selective process for periplasmic protein incorporation in
OMVs.
The high rate of success in targeting recombinant
antigens to the lumen of OMVs (in essence, all hetero-
logous antigens we have tested so far were successfully
incorporated into bacterial vesicles) could appear sur-
prising. Indeed, it has been demonstrated that binding
of the leader peptide to the ATP motor protein SecA is
necessary but not sufficient for protein secretion through
the sec-dependent pathway and that concomitant SecA
binding by conserved motifs in mature proteins is also
required (35,36). This is why many cytoplasmic proteins
that do not carry SecA-binding motifs cannot reach the
periplasm even when fused to leader peptides. To explain
the efficiency of our OMV protein delivery, it has to be
pointed out that we focused our attention on hetero-
logous bacterial antigens inducing protective antibody
responses. Many of these antigens, such as those selected
for this study, belong to the category of proteins that
are naturally secreted or surface-exposed by the sec-
dependent pathway. Therefore, these proteins are the
ideal candidates to be expressed in the E. coli periplasm
as long as an E. coli-compatible leader sequence is fused
to their N-termini. It is in fact known that leader
Fig. 8. In vivo protective activity of Slo-OMVs and SpyCEP-
OMVs  Groups of 16 mice were immunized with 3 doses of
Alum-formulated OMVs carrying heterologous antigens (25 mg
total proteins), Alum-formulated purified recombinant proteins
(20 mg) or Alum alone. After 2 weeks, mice were challenged
intraperitoneally with a LD80 dose of M1 3348 GAS (210
6
CFUs) and survival was followed over a period of 7 days.
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sequences can be species-specific, and in particular leader
sequences of Gram-negative bacteria differ from those of
gram-positive species (37). In this study, we have used the
OmpA leader sequence for antigen secretion, but other
leader sequences are expected to work as well and indeed
to achieve optimal secretion levels we are currently testing
each antigen with a battery of different E. coli leader
sequences.
Antigens inducing antibody-mediated protective activ-
ity include members of the integral membrane family and
proteins that are secreted via alternative secretion path-
ways. Although not tested in this work, such proteins
are likely to be less prone to OMV delivery through
fusion to leader sequences, and other strategies might be
required to achieve their expression in OMVs.
The second question we addressed in this study is
whether immunization with OMVs carrying antigens in
their lumen can induce antigen-specific antibodies. The-
oretically speaking, localizing antigens inside the vesicles
should prevent antigen-specific B cell binding and the
consequent proper stimulation of antibodies. To the best
of our knowledge, only 2 groups have so far analyzed
immune responses against luminal recombinant antigens
(32,33). Both groups have reported the elicitation of
antigen-specific antibodies, but titers were relatively
low and the authors reached the conclusion that, for
practical vaccine application, antigens should be loca-
lized on the OMV surface. In the case of pneumococcal
PspA expression in Salmonella OMVs, the authors
presented evidence that the protein was released into
the growth culture supernatants in addition to being
localized in the periplasm/OMV lumen. Therefore, the
observed PspA-specific antibodies could have been at
least partially generated by the secreted protein ‘‘con-
taminating’’ the OMV preparation.
Our data unequivocally demonstrate that recombinant
antigens delivered to the lumen of OMVs do induce
effective antibody responses. Indeed, antibody titers were
often close to those obtained with 20 mg of recombinant
proteins, corresponding in some cases to 1 log higher
antigen amounts than those carried in the 25 mg of OMVs
doses used for mouse immunization. Most important,
antibodies were characterized by a functional activity
which could be greater than the one observed with
sera from animals immunized with the correspond-
ing recombinant proteins. This is particularly evident for
SAM_1372-OMVs: despite the fact that the protein
induced low ELISA titers (most likely because of its poor
expression in OMVs) antibodies had an excellent func-
tional activity in terms of bacterial opsonophagocytic
killing.
Elicitation of high-quality antibodies translated into
good protection in vivo, as judged by the ability
of animals immunized with SpyCEP-OMVs and Slo-
OMVs to survive GAS lethal challenges. At least 2
important factors contribute to such potent functional
responses. First, all antigens used in this work preserved
their native conformation when expressed in the lumen of
OMVs, as deducible from the fact that the antigens had
fully enzymatic/toxic activity. This guaranteed the elici-
tation of conformational antibodies capable of binding
and neutralizing the antigen toxic activities. Second,
and particularly important, recombinant OMVs have
the intrinsic ability to co-deliver antigen and adjuvant
to the same antigen-presenting cells, thus allowing the
optimal activation of antigen-specific B- and T-cells (38).
The relevance of antigen/adjuvant co-delivery can be
appreciated when the inhibition of SpyCEP proteolytic
activity by antibodies induced by 2 injections of different
SpyCEP-containing vaccine formulations was compared
(Fig. 7). Sera from SpyCEP-OMVs immunized animals
showed a higher neutralization activity with respect
to both Alum-formulated recombinant SpyCEP and
SpyCEP mixed with ‘‘empty’’ OMVs. While the anti-
gen-adjuvant co-delivery concept can explain how APCs
taking up SpyCEP-OMVs optimally stimulate the gen-
eration of SpyCEP-specific plasma cells and memory
B cells, the presentation of a luminal protein to naı¨ve B
cells necessarily requires that the integrity of OMVs is
partially compromised in order to expose the protein to B
cell receptors. Based on the foregoing, we propose that
OMVs are taken up at the site of injection by APCs,
which present the antigen-specific peptides to T cells. At
the same time, a fraction of OMVs are degraded before
being phagocytosed by APCs and this allows antigen
presentation to naı¨ve B cells. Antigen-specific B cells
are finally stimulated to become effector and memory B
cells by interaction with antigen-specific Helper T cells
generated by those APCs that have taken up intact
vesicles. According to this model, the ratio between
intact and degraded OMVs at the site of injection is
expected to be important for the generation of a
sufficiently large population of antigen-specific T- and
B-cells and, ultimately, a good antibody response. The
extent of vesicle degradation should be determined by
a number of factors, including site of immunization,
formulation and nature of OMVs. In this respect, it
has to be pointed out that the strains used for vesicle
production and engineering usually carry specific muta-
tions that confer an OMV-overproducing phenotype.
Many of these mutations have a direct effect on the
integrity of the outer membrane or on the interaction
between outer and inner membranes (39). In this study
we used a BL21 E. coli strain carrying the ompA gene
deletion, which results in the removal of one of the major
membrane proteins in E. coli. It is possible that the
OMVs derived from this mutant are sufficiently robust/
fragile to induce the good antigen-specific antibody
responses we observed in our work. Other mutations
could generate vesicles with different chemicalphysical
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properties and this could ultimately affect immune
responses both qualitatively and quantitatively.
The reactogenicity of OMVs and the implication of
such reactogenicity in OMV-based vaccine develop-
ment deserve one last comment. It is well known that
OMVs carry large amount of LPS. We measured the LPS
content in our OMV preparations and determined an
LPS:protein ratio of approximately 0.5 (50 ng of LPS/100
ng of OMV proteins). This number is consistent with
that recently reported by Park and co-workers (40).
Such LPS concentrations are toxic in mice and 20 mg
of E. coli OMVs injected intraperitoneally have been
shown to be sufficient to rapidly kill animals (40). This
is the reason why, to decrease OMV reactogenicity,
throughout this work OMV immunization was carried
out in the presence of Alum, which absorbs LPS and
prevents its systemic dissemination. However, for human
use, OMVs must be detoxified. This can be achieved in
at least 2 ways. One possibility is to remove LPS using
detergent extraction. For instance, the meningococcal
OMV-based vaccines available on the market are pro-
duced by deoxycholate treatment of whole bacteria.
A second approach is to use OMVs deriving from mutant
strains that carry detoxified variants of LPS. Mutations
that produce detoxified OMVs have been described
for Neisseria meningitidis (41) and E. coli (42). Interest-
ingly, a synthetic biology methodology has recently been
reported that allows modulating the innate immune
response of LPS by engineering the LPS biosynthetic
pathway of E. coli (43). We are pursuing similar
approaches to design OMVs with TLR4 agonist activities
tailored on the basis of specific vaccine needs.
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